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MITOCHONDRIAL LYSINE ACETYLTRANSFERASE IN THE PROTOZOAN 
PATHOGEN TOXOPLASMA GONDII 
 
 
Toxoplasma gondii, a single-celled eukaryotic pathogen, has infected one-
third of the world’s population and is the causative agent of toxoplasmosis. The 
disease primarily affects immunocompromised individuals such as AIDS, cancer, 
and transplant patients. The parasites can infect any nucleated cell in warm-
blooded vertebrates, but because they preferentially target CNS, heart, and 
ocular tissue, manifestations of infection often include encephalitis, myocarditis, 
and a host of neurological and ocular disorders. Toxoplasma can also be 
transmitted congenitally by a mother who becomes infected for the first time 
during pregnancy, which may result in spontaneous abortion or birth defects in 
the child. Unfortunately, the therapy currently available for treating toxoplasmosis 
exhibits serious side effects and can cause severe allergic reactions. Therefore, 
there is a desperate need to identify novel drug targets for developing more 
effective, less toxic treatments. The regulation of proteins via lysine acetylation, a 
reversible post-translational modification, has previously been validated as a 
promising avenue for drug development. Lysine acetyltransferases (KATs) are 
responsible for the acetylation of hundreds of proteins throughout prokaryotic and 
eukaryotic cells. In Toxoplasma, we identified a KAT that exhibits homology to 
Elongator protein 3 (TgElp3), the catalytic component of a transcriptional 
elongation complex. TgElp3 contains the highly conserved radical S-
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adenosylmethionine and KAT domains but also possesses a unique C-terminal 
transmembrane domain (TMD). Interestingly, we found that the TMD anchors 
TgElp3 in the outer mitochondrial membrane (OMM) such that the catalytic 
domains are oriented towards the cytosol. Our results uncovered the first tail-
anchored mitochondrial KAT reported for any species to date. We also 
discovered a shortened form of Elp3 present in mouse mitochondria, suggesting 
that Elp3 functions beyond transcriptional elongation across eukaryotes. 
Furthermore, we established that TgElp3 is essential for parasite viability and 
that its OMM localization is important for its function, highlighting its value as a 
potential target for future drug development. 
 
William J. Sullivan, Jr., Ph.D., Chair 
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I. INTRODUCTION 
 
A. Toxoplasma gondii, a eukaryotic pathogen 
 Toxoplasma gondii is a single-celled, eukaryotic protozoan belonging to 
the Phylum Apicomplexa. This hardy obligate, intracellular organism has the 
ability to infect any nucleated cell in warm-blooded animals, making it a powerful 
parasite that affects human health, and livestock production. Toxoplasma is also 
widespread, infecting about one-third of the world’s population all around the 
globe (1). As the causative agent of the disease toxoplasmosis, Toxoplasma is 
medically important in its own right, but its close relatives also cause devastating 
disease and have enormous socioeconomic consequences. Other members of 
the phylum include Plasmodium spp., Cryptosporidium spp., and Babesia spp. 
Malaria, caused by Plasmodium, kills over half a million people a year (2), and 
Cryptosporidium infections are one of the leading causes of waterborne illness in 
the United States (3). Many apicomplexan species can infect livestock in addition 
to humans and cause millions of dollars in economic loss. Toxoplasma and its 
close relatives are successful pathogens that must be investigated for the 
advancement of science and medicine.  
 While the genus Toxoplasma contains only one species, Toxoplasma 
gondii, distinct strains within the species have been characterized. Three major 
lineages, types I, II and III, have been identified that are proposed to have shared 
a common ancestor approximately 10,000 years ago (4). Several differences 
exist between the strains including virulence, growth rate, and cyst formation (5). 
Type I strains replicate quickly, have reduced cyst-forming capacity, and are 
hypervirulent. Type I strains such as RH are commonly used in the laboratory 
setting due to their fast doubling time and their amenability to genetic 
manipulation. RH parasites were named after the initials of the patient they were 
isolated from in 1938, and all Toxoplasma studies in this thesis used either RH 
parasites or a genetically modified form of RH. Type II and III strains are 
hypovirulent, grow slower than type I, and readily form bradyzoite cysts. These 
strains, particularly type II, are the most common found in humans and are often 
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used in animal and in vitro experiments to study tachyzoite and bradyzoite 
differentiation. Despite their phenotypic differences, the three strains differ by 
only about 1% genetically (5).  
 As an early-branching single, eukaryotic cell, Toxoplasma’s cellular 
content is made up of conserved eukaryotic features in addition to some that are 
parasite-specific (Figure 1). Toxoplasma cells contain a nucleus, endoplasmic 
reticulum (ER), golgi apparatus, and a single mitochondrion. Parasite-specific 
structures include the rhoptries, conoid, and micronemes, important for host cell 
detection, attachment, and invasion, as well as an apicoplast, a chloroplast-like 
remnant from an early symbiont form (6). Cellular functions can also be classified 
as well-conserved eukaryotic processes or parasite-specific processes. Several 
components of transcription, translation, metabolism, and signaling are similar to 
those in many eukaryotic cells, but the lack of homology and divergence of 
factors involved in many pathways suggests that these organisms are unique. 
For example, Toxoplasma contains the highly conserved RNA polymerase II for 
transcription but apparently lacks eukaryotic transcription factors such as p53. 
Instead, the parasites possess unique plant-like AP2 domain-containing factors 
thought to serve as transcription factors. As a result, by studying Toxoplasma we 
can both unearth biological secrets that are preserved in eukaryotes from 
parasites to humans and identify ways of specifically targeting the parasites for 
therapeutic benefit.   
Powerful tools facilitate the study of Toxoplasma. The organism is easily 
maintained in culture and is amenable to genetic manipulation. The Toxoplasma 
genome has been sequenced and is available on the online database ToxoDB 
(www.toxodb.org). This database is also a repository for datasets from other “-
omic” studies including expression data, mass spectrometry analyses, and post-
translational modifications.  
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Figure 1: Depiction of Toxoplasma organelles. Eukaryotic organelles present in 
Toxoplasma include the nucleus, endoplasmic reticulum, golgi apparatus, and a 
single mitochondrion. Dense granules, rhoptries, micronemes, conoid, and a 
single apicoplast are structures specific to apicomplexans. Toxoplasma 
tachyzoites are approximately 2 x 6 µm in size. 
 
 
B. Toxoplasma life cycle 
 The complex life cycle of Toxoplasma contains both sexual and asexual 
stages with differentiation of the parasite into different forms - sporozoite, 
bradyzoite, and tachyzoite. When ingested by its definitive host, members of the 
Felidae family, parasites reproduce sexually within the cat’s intestines and form 
sporozoite-containing oocysts that are excreted into the environment (Figure 2) 
(6). Oocysts can be ingested directly from contaminated soil and water by 
animals, including humans, birds, mice, and livestock, that serve as 
intermediumte hosts. Once ingested, sporozoites are released from the oocysts 
and differentiate into tachyzoites.  
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 Tachyzoites are the rapidly replicating form of the parasite, doubling 
approximately every 6-10 hours depending on the strain. Toxoplasma division 
occurs through a process termed endodyogeny. This form of asexual 
reproduction involves the formation of two daughter cells within the original 
mother cell. As tachyzoites invade tissues in the intermediumte host, they are 
signaled by changes in the immune system, such as increases in interferon 
gamma, and potentially other unidentified components, to differentiate into 
bradyzoites (7,8). Bradyzoites are slow-growing and form cysts that reside 
permanentely in tissues, particularly in neural, cardiac, and muscle tissue. Cysts 
embedded in the tissues of an intermediumte host can then be consumed by 
other animals, thus passing on the infection. If a cat ingests bradyzoites from an 
infected mouse or bird, the life cycle of Toxoplasma has been completed (Figure 
2). 
 
 
Figure 2: Diagram of the life cycle of Toxoplasma. Parasites reproduce sexually 
within the gut of cats, the definitive host. Cats then shed oocysts into the 
environment, which are subsequently ingested by animals including humans. 
Within the intermediumte hosts, Toxoplasma differentiates into fast replicating 
tachyzoites and then slow-growing bradyzoites. Bradyzoites form cysts in tissue 
and can be transmitted via consumption of the infected animal. The life cycle is 
considered complete when a cat ingests bradyzoites from infected prey or 
oocysts from the environment. Humans can vertically transmit tachyzoites to the 
fetus from a mother infected for the first time during pregnancy. 
	   5 
C. The disease toxoplasmosis 
 The human disease toxoplasmosis is caused by Toxoplasma infection. As 
previously mentioned, bradyzoites form tissue cysts that remain in the host 
permanently. The immune system is able to keep the parasites dormant and 
prevent reactivation of the bradyzoites into the actively dividing tachyzoites. In 
healthy individuals with a functioning immune system, Toxoplasma infection can 
be asymptomatic or cause mild flu-like symptoms. However, when an infected 
individual becomes immunocompromised, parasites are triggered to differentiate 
into tachyzoites. As a result, tissue is massively destroyed as the parasites 
quickly replicate, killing host cells in the process.  
Toxoplasmosis primarily affects those whose immune system has been 
compromised such as patients with AIDS, cancer, or organ transplants and is 
often classified as an opportunistic infection (9,10). Disease manifestations 
commonly include myocarditis, encephalitis, ocular disease, and neurological 
disorders (11). In extreme cases the disease can be fatal. Toxoplasma can also 
cause congenital toxoplasmosis, as tachyzoites can be vertically transmitted from 
a first-time infected mother to her fetus. Fetal infection can result in spontaneous 
abortion or congenital defects. Infants often suffer from hydrocephalus, vision 
and hearing impairments, and cognitive disorders.   
Toxoplasma causes a chronic life-long infection and, with preference for 
neural tissue, can reside dormant in the brain. While acute symptoms may not be 
observed, researchers have examined the ability of these parasites to alter 
behavior in their hosts. Studies have shown that rodents infected with 
Toxoplasma have lost their aversion to cats and may actually be attracted to cat 
urine, thus making it easier for cats to ingest the infected rodent and complete 
the parasite’s life cycle (12-14). In humans, Toxoplasma infection has been found 
to have an association with several neurological disorders including 
schizophrenia, suicide, obsessive-compulsive disorder, bipolar disorder, and 
psychosis (15-19). Currently, the data does not prove causation but increasing 
evidence suggests Toxoplasma may play a role in modifying human behavior. 
While mechanisms underlying these changes are not fully understood and are 
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likely attributed to several factors, Toxoplasma’s effect on dopamine may be 
involved. Several neurological disorders are a result of or treated by changes in 
dopamine. One study showed that dopamine levels are significantly increased in 
Toxoplasma-infected mouse brains (20), and further analysis revealed high 
levels of dopamine in tissue cysts (21). In addition, the Toxoplasma genome 
harbors a tyrosine hydroxylase gene, the rate-limiting enzyme in dopamine 
synthesis, which may contribute to the increase in dopamine (22). Another study 
found that the parasites functionally silence the neurons they infect, potentially 
altering function in the brain (23).      
Several methods are employed to diagnose toxoplasmosis and detect the 
presence of Toxoplasma. Serological tests are common for detecting the 
presence of antibodies and some can be used to determine if the infection 
occurred recently or in the distant past. The Sabin-Feldman dye test served as 
the gold standard for many years after it was published in 1948 (24). This test 
relies on the lysis of parasites by antibodies in the patient’s serum in the 
presence of complement and is visualized by the addition of a dye that stains 
intact parasites. While the Sabin-Feldman dye test is still used today, a number 
of other serological tests have been developed to recognize Toxoplasma 
antibodies including the enzyme-linked immunosorbent assay (ELISA), the 
modified agglutination assay, the indirect fluorescent antibody assay, and the IgG 
avidity test (25). Comparative Western blots can also be conducted between 
serum from a mother and child to determine congenital infection. In addition to 
serological tests, polymerase chain reaction (PCR) and real-time PCR have 
become widely used to detect Toxoplasma infection. Other techniques, useful in 
certain circumstances, include immunohistochemistry, mouse inoculation, and 
electron microscopy. As a result of the varied specificity and reliability of these 
tests, combinations of several detection methods are used in the diagnosis of 
toxoplasmosis.  
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D. Toxoplasmosis treatment 
 Toxoplasmosis cannot be cured but therapies are available for treating 
acute infection. The primary treatment is combined therapy with sulfadiazine and 
pyrimethamine, which targets the folic acid synthesis pathway (Figure 3) (26). 
Pyrimethamine inhibits the enzyme dihydrofolate reductase (DHFR), present in 
both parasites and humans. Despite having a slightly higher affinity for the 
Toxoplasma enzyme, pyrimethamine causes toxicity in humans, and side effects 
of DHFR inhibition include bone marrow suppression. Therefore, this treatment is 
supplemented with folinic acid to reduce side effects. Since pyrimethamine is 
teratogenic, suppresses bone marrow, and can cross the placenta, this therapy is 
not recommended for pregnant women, especially during the first trimester. 
Instead, spiromycin, a non-toxic macrolide unable to cross the placenta, is used 
to treat infected pregnant women to prevent or reduce transmission to the fetus 
(25). Therefore, it is used to reduce parasite burden in the mother but cannot be 
used to treat the fetus. In cases where the fetus is suspected of being infected 
after the first trimester, the combinational therapy of pyrimethamine, sulfadiazine, 
and folinic acid is administered.  
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Figure 3: Illustration of the pathway targeted by drugs used to treat 
toxoplasmosis. A combination of sulfadiazine and pyrimethamine is used to treat 
toxoplasmosis by targeting the pathway for folic acid synthesis. Sulfadiazine 
inhibits dihydropteroate synthase (DHPS), an enzyme not present in humans, 
and pyrimethamine inhibits dihydrofolate reductase (DHFR). DHFR is present in 
both Toxoplasma and humans but pyrimethanime has a slightly stronger affinity 
for the parasite enzyme. This therapy kills parasites by inhibiting the synthesis of 
nucleic acids precursors.  
 
 
Unfortunately, these therapies are limited and can cause serious side 
effects and allergic reactions. As already mentioned, pyrimethamine can have 
toxic side effects including bone marrow suppression, and patients can develop 
allergies to sulfadiazine. The antibiotic clindamycin, which poisons the parasite’s 
unique apicoplast organelle, can be used in cases where the patient is unable to 
tolerate the traditional treatment regimen but very few other alternative 
treatments exist. All drugs currently used for treating toxoplasmosis target only 
the acute and not the chronic form of infection. Bradyzoite cysts that permanently 
reside in host tissue cannot be eradicated by the immune system or any of the 
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current therapies. Current research focuses on studying molecular parasitology 
in order to identify alternative therapies.  
 
E. Targeting lysine acetylation 
 One area of parasite biology that has been validated as a potential 
therapeutic target is lysine acetylation. Acetylation is a dynamic and reversible 
post-translational modification found in nearly every species that can regulate a 
protein’s function by modifying its localization, interactions, enzymatic activity, or 
stability. Lysine acetyltransferases (KATs) and lysine deacetylases (KDACs) are 
the enzymes responsible for the addition and removal of acetyl groups, 
respectively, to or from the ε-amino group of lysine residues (Figure 4). 
Acetylation of a lysine residue neutralizes the positive charge, thereby altering 
the electrostatic properties of the protein. Targeted disruption of this form of 
protein regulation has been revealed to have therapeutic benefits. The natural 
product apicidin is a KDAC inhibitor that was first discovered as having anti-
protozoal activity (27) and is now used in cancer therapies (28). Trichostatin A, 
another KDAC inhibitor, was also shown to have anti-parasitic effects (27). These 
KDAC inhibitors demonstrate the importance of acetylation in protozoan 
parasites and highlight the need for studying Toxoplasma KATs and KDACs. Our 
laboratory has characterized several KATs in Toxoplasma and shown them to be 
important for parasite gene expression, differentiation, DNA repair, and survival 
in the parasites (29-32).  
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Figure 4: Chemical depiction of protein acetylation. The acetyl group (blue) is 
transferred from acetyl-CoA to the amine of a lysine residue by a KAT enzyme. 
The acetyl group is removed from lysine residues by KDACs.  
 
 
 For many years, KATs and KDACs were only known to regulate histone 
acetylation and were therefore referred to as histone acetyltransferases (HATs) 
and histone deacetylases (HDACs). Today, these enzymes are more accurately 
referred to as KATs and KDACs since they are now known to modify lysine (K) 
residues on a wide range of proteins. KATs, the enzymes responsible for protein 
acetylation, were first characterized in 1995 when GCN5 (general control non-
derepressible 5) was purified from the free-living protozoan Tetrahymena 
thermophile (33). GCN5 was found to be highly conserved from yeast to humans 
and was identified as a key regulator of transcription via acetylation of histone 
tails. Since the discovery of GCN5, novel KATs continue to be identified. They 
are generally classified as belonging to one of three families depending on the 
sequence of their catalytic domain, although additional categories have been 
established. The three major families include GNAT (GCN5-related N-
acetyltransferase), p300 (E1A-associated protein of 300 kDa)/ CBP [CREB 
(cAMP-response-element-binding protein)-binding protein], and MYST, named 
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for the proteins originally identified - MOZ (monocytic leukaemic zinc-finger 
protein), Ybf2/Sas3, Sas2 and TIP60 (Tat-interactive protein 60 kDa) (34). 
 KDACs, enzymes that deacetylate lysine residues, are organized into four 
classes (I, II, III, and IV) based on sequence homology. Classes I, II, and IV are 
“classical” KDACs that have a similar mechanism of action, while class III KDACs 
are referred to as sirtuins based on homology to a yeast gene called silent 
mating-type information regulation 2 (Sir2). Sirtuins require the cofactor NAD+ to 
catalyze the removal of an acetyl group. Recently, mitochondrial sirtuins, 
particularly SIRT3, have gained a lot of attention because of their role in 
regulating metabolism and other mitochondrial functions. While mitochondrial 
KDACs have been identified and found to be critical for function (35), a 
mitochondrial-localized KAT has remained elusive. 
 A number of natural and chemically engineered inhibitors of both KATs 
and KDACs have been used over the years but most still lack the ability to be 
therapeutically beneficial due to poor pharmacological properties and a lack of 
specificity. Anacardic acid, garcinol, and curcumin are all natural products found 
to inhibit KATs (36-38), but studies indicate that they also interfere with other 
pathways in the cell (39-41). Synthetic peptide-CoA bisubstrate inhibitors have 
also been designed as highly specific KAT inhibitors but have poor cell 
permeability (42). The aforementioned KDAC inhibitors apicidin and trichostatin A 
have anti-protozoal activity but are ineffective for treating humans. Additional 
KDAC inhibitors include suberyllanilide hydroxamic acid (SAHA), sodium 
butyrate, valproate, and tubacin (43-45). Nicotinamide has also been shown to 
be a specific inhibitor of sirtuins (46,47). Targeting the regulators of lysine 
acetylation would be beneficial for treating several types of diseases including 
Toxoplasma infection. However, current compounds have many shortcomings, 
and in order to design more specific KAT and KDAC inhibitors, we must learn 
more about the enzymes and their targets.  
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F. Global protein acetylation 
 The functional diversity of a cell’s proteome is greatly expanded through 
covalent post-translational modifications such as phosphorylation, SUMOylation, 
acetylation, ubiquitination, and methylation. Post-translational modifications are 
critical for identifying and responding to internal and external stimuli from 
changes in the environment. Phosphorylation has been well-studied and is 
understood to be a global player in regulating cellular functions. Only recently 
has lysine acetylation emerged as a prominent regulator of multiple cellular 
processes including transcription, metabolism, cell cycle, and apoptosis. While 
the core histones were known to be highly acetylated for more than 50 years, 
identification of the first non-histone protein to be acetylated did not occur until 
1997 with the discovery that the acetylation of the transcription factor p53 
affected its DNA binding activity (48). Then, with the advancement of technology, 
it became possible to identify acetylation sites of entire proteomes, termed 
“acetylomes”. The first proteome-wide analysis of lysine acetylation sites was 
conducted in 2006 in HeLa cells and mouse mitochondria and identified 388 
lysines acetylated on 195 proteins; 277 of the acetylation sites were found on 
mitochondrial proteins (49). This study showed conclusively for the first time that 
lysine acetylation was widespread and also abundant in the mitochondria. 
Recent acetylomes, using more high-resolution mass spectrometry, have 
revealed over a thousand acetylated proteins in bacterial, plant, protozoan, and 
metazoan species, suggesting that acetylation may rival phosphorylation in 
regards to its universality and regulatory power (50-55).  
 
G. The Toxoplasma acetylome 
 In order to determine the scope of lysine acetylation in Toxoplasma, our 
laboratory recently analyzed the Toxoplasma acetylome of intracellular and 
extracellular tachyzoites by using pan acetyl-lysine antibodies and mass 
spectrometry to enrich for and identify acetylated peptides, respectively. This 
study was the first acetylome analysis conducted in a single-celled eukaryotic 
organism and resulted in the identification of 718 acetylated residues on 482 
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proteins (54,56). It uncovered a diverse array of acetylated proteins, both 
conserved and parasite-specific. In Toxoplasma, much of the proteome consists 
of hypothetical proteins that have little or no homology to characterized proteins. 
Therefore, the majority of acetylated proteins were found to be hypothetical 
(Figure 5). However, the remaining acetylated proteins were annotated as 
belonging to nearly every cellular pathway and present in all organelles 
throughout the parasite (Figure 5). Twenty confirmed and predicted mitochondrial 
proteins were found to be acetylated including isocitrate dehydrogenase, heat 
shock protein 60, ATP synthase, cytochrome c, and the outer mitochondrial 
membrane protein porin. Consistent with other species, acetylation in 
Toxoplasma is widespread and suggests that lysine acetylation plays a critical 
role in cellular function. 
 
 
Figure 5: Proteins involved in nearly every parasite cellular process are 
acetylated. The pie chart of proteins found to be acetylated in Toxoplasma is 
categorized by functional group. The majority of acetylated proteins are either 
hypothetical or involved in translation, metabolism, stress response, and 
chromatin biology (54, 56).    
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While studies have led to the identification of a large number of previously 
unknown acetylated residues, these acetylomes are still not comprehensive due 
to various limitations. For example, acetylome analyses are a snapshot of cellular 
acetylation during a single timepoint under one set of experimental conditions. 
Also, due to the lack of a consensus sequence surrounding acetylated residues, 
identification of acetylated residues is limited by the specificity of the antibodies 
used for affinity-enrichment of peptides. Large-scale acetylome analyses have 
proven useful but studies of individual acetylated proteins and the enzymes 
responsible for their acetylation are still required in order to fully understand the 
role of this post-translational modification in cellular biology.  
 
H. Toxoplasma KATs  
 Based on homology searches, eight KATs and seven KDACs have been 
identified in the Toxoplasma genome to date. Our laboratory has previously 
identified and characterized two GCN5 KAT homologues, TgGCN5-A and 
TgGCN5-B, and two homologues in the MYST family, TgMYST-A and TgMYST-
B.  Both of the Toxoplasma GCN5s were found to be localized exclusively in the 
nucleus and to acetylate histone H3 (30). TgGCN5-B appears to be essential for 
tachyzoite survival, and TgGCN5-A, while dispensible in tachyzoites, regulates 
stress-induced gene expression during differentiation (32). Unlike the GCN5s, 
TgMYST-A and TgMYST-B are both nuclear and cytosolic, and TgMYST-A has 
been shown to preferentially acetylate histone H4 in vitro (31). Attempts to 
knockout or over-express TgMYST-A have been unsuccessful, suggesting that it 
is essential, and its expression levels are highly regulated. TgMYST-B has been 
implicated in regulating transcription and the response to DNA damage (29). 
Another laboratory has identified a homologue of TAF1/250 (TATA box binding 
protein-associated factor, 250 kDa) and found it to be essential in Toxoplasma 
(57). Toxoplasma also has predicted homologues of Hat1 (histone 
acetyltransferase 1), αTAT1 (alpha tubulin acetyltransferase 1), and Elp3 
(Elongator protein 3). Characterization of these additional KATs will be vital to 
understanding acetylation in Toxoplasma and how it may be targeted 
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therapeutically. This dissertation focuses on the characterization and unique 
properties of the Toxoplasma Elp3 homologue (TgElp3).   
 
I. History of the Elongator protein 3 (Elp3) KAT 
Before 2009, very little was known about Elp3 and its role in cellular 
biology. It was first identified ten years earlier in yeast when it was 
immunoprecipitated as part of a complex with RNA polymerase II during 
transcription elongation (58,59). Elp3 was found to be the catalytic component of 
a six-subunit complex (Elp1-6) termed the Elongator complex and is highly 
conserved from archaebacteria to humans. Elp3 contains two highly conserved 
domains, a KAT domain belonging to the GNAT family and a radical S-
adenosylmethionine (radical SAM) domain.  
The presence of a radical SAM domain is unique to the Elp3 family of 
KATs and its function is unclear. In general, radical SAM domains do not have a 
specific function, but rather they can participate in a number of catalytic activities, 
such as oxidation-reduction, isomerization, methylation, and protein radical 
formation, which seem to be specific to the protein or its targets (60). The 
function of this domain in Elp3 orthologues is not well understood, but the 
Methanocaldococcus jannaschii homologue was used to confirm that it can form 
iron-sulfur clusters and bind SAM, suggesting Elp3 has catalytic activity (61). By 
mutating the radical SAM domain, it has been shown to be important for DNA 
demethylation in mouse zygotes and critical for the function of the Elongator 
complex (62). 
As radical SAM domains are poorly understood and can have multiple 
functions, Elp3 has primarily been studied for its role as an acetyltransferase. A 
combination of in vitro and in vivo studies shows that Elp3, as part of the 
Elongator complex, can acetylate histones H3 and H4, preferentially targeting H3 
in vivo (63,64). While KATs such as GCN5 were thought to primarily acetylate 
histones near gene promoters to regulate transcription initiation, the Elongator 
complex was found to be located within gene bodies regulating transcription 
elongation (65,66). The proposed model describes Elp3 as acetylating H3 as part 
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of a transcription elongation complex in order to open chromatin during gene 
transcription. This role of Elp3 has been confirmed in yeast, plant, and 
mammalian species (66-69). 
Several studies have confirmed Elp3 as a KAT involved in transcription, 
yet Elp3 was revealed to be largely cytoplasmic. In 2009, Creppe et al provided 
exciting new evidence that Elp3 acetylates alpha-tubulin in the cytoplasm of 
human and mouse cells and that this function of Elp3 was necessary for cortical 
neuron growth and differentiation (70). This study not only identified a 
cytoplasmic substrate of Elp3 but also uncovered the previously unknown alpha-
tubulin acetyltransferase that acetylates the highly conserved lysine 40 residue 
residing within the lumen of microtubules. These findings sparked a renewed 
interest in Elp3 and its functions outside of transcription. Subsequent studies 
showed Elp3-mediumted acetylation of alpha-tubulin in other species and 
examined the effect of acetylation on tubulin (71). Evidence suggests that 
acetylation may stabilize microtubules and/or contribute to kinesin transport 
(72,73). Later, a second tubulin acetyltransferase was discovered, αTAT1 or 
MEC-17 (mechanosensory abnormality protein 17), which is now thought to be 
the primary tubulin acetyltransferase (74,75). Elp3 was shown to have weak 
tubulin acetylation activity compared to that of αTAT1, and while αTAT1 could 
acetylate tubulin in PtK2 [Potorous tridactylus (kangaroo rat) kidney] cells, Elp3 
could not produce detectable levels of acetylation (75). In addition, C. elegans 
touch receptor neurons, which contain high levels of tubulin acetylation, require 
αTAT1 for tubulin acetylation and retain acetylated tubulin in the absence of Elp3, 
suggesting that αTAT1 is the primary tubulin acetyltransferase (74,75).  
Another independent cytoplasmic function of Elp3 was uncovered when 
several groups found that the Elongator complex modifies uridines at the wobble 
position of tRNAs (76,77). tRNA modifications, especially at the wobble position 
(position one of the anticodon), are important for proper translation efficiency and 
fidelity and can be used to regulate expression at the level of translation (78). 
The Elongator complex was found to be responsible for the addition of a 
methoxycarbonylmethyl (mcm) and carbamoylmethyl (ncm) group to the C5 
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uridine nucleoside at the wobble position, resulting in the mcm5s2U (5-
methoxycarbonylmethyl-2-thiouridine) and ncm5U (5-carbamoylmethyluridine) 
modifications, respectively.  Interestingly, over-expression of these modified 
tRNAs suppressed all Elongator/Elp3 mutant phenotypes, further confirming 
these tRNA modifications as an established role of Elp3 (79). The mechanism of 
tRNA modification by Elp3 is unknown and it is unclear if the function of the KAT 
and/or radical SAM domain is involved.   
Elp3 deletions, knockdowns, and mutations have resulted in a number of 
different phenotypes depending on the cell type or organism. In yeast, Elp3 is 
dispensable but deletion causes growth defects when yeast are exposed to 
stresses such as changes in temperature and osmotic conditions (58,59,64). In 
addition, cells are hypersensitive to transcriptional inhibitors such as 
mycophenolic acid and 6-azauracil. Human Elp3 (hElp3) was shown to be 
functionally similar to the yeast homologue, as hElp3 was able to complement an 
Elp3 knockout in yeast (80). A similar complementation experiment was done 
with plants (77), suggesting the yeast, plant, and human Elp3 homologues are 
similar in structure and function. Elp3 mutations in plants resulted in changes in 
leaf morphology and polarity as well as a reduction in organ growth (81,82).  
While Elp3 does not appear to be essential in certain cell lines, yeast, or 
plants, disruption in Drosophila melanogaster causes lethality during pupal 
development (83). A targeted knockdown of Elp3 in the Drosophila nervous 
system is not lethal but affects synaptic bouton expansion and axonal length, 
indicating a role of Elp3 in neurodevelopment (84). The importance of Elp3 in 
neuronal development was also seen in Caenorhabditis elegans when mutations 
resulted in impaired neuronal migration and axonal extension (71). Knockdown of 
Elp3 using shRNA also impairs the migration and differentiation of mouse cortical 
projection neurons by causing a reduction in alpha-tubulin acetylation (70). Few 
studies have examined the effect of mutating both catalytic domains (KAT and 
radical SAM) or made direct comparisons between mutations in either domain. 
However, one study found that both domains are essential for the function of 
Elp3 in basal and effector-triggered immunity in plants (85).  
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J. Elp3 and human disease 
 Modifications of Elp3 are associated primarily with neurological disorders 
in humans. Both Elp1 and Elp3 of the Elongator complex have been correlated 
with familial dysautonomia (FD), an autosomal recessive disease that affects the 
sensory and autonomic nervous system causing defects in neuronal 
development (86,87). The major cause of FD is a mutation in Elp1 that affects 
splicing, resulting in a truncated form of the protein. Low levels of Elp3 
expression have also been found in FD patients. In addition, FD neuronal cells 
have reduced motility in vitro, a key phenotype often seen with disruption of Elp3. 
Another disease that causes the degeneration of motor neurons, amyotrophic 
lateral sclerosis (ALS), has been found to be associated with allelic variations of 
Elp3. Elp3 was identified in a genome-wide association study of 1,483 individuals 
from three human populations as being correlated with ALS (88). In addition, 
lower levels of Elp3 expression in the brain were associated with risk-associated 
alleles of the Elp3 gene in humans. Two loss-of-function mutations (R475K and 
R456K) were found to be important for neuronal survival in Drosophila, and 
knockdown of Elp3 in zebrafish resulted in abnormal branching of neurons (88), 
suggesting that Elp3 may play a role in neurological disorders.   
 
K. Summary and hypotheses 
 Toxoplasma is a clinically relevant pathogen that causes both acute and 
chronic infection. Few drugs are available for treating acute infection, and they 
often have serious side effects and/or cause allergic reactions. In addition, the 
chronic form of infection is currently untreatable. Novel drug targets need to be 
identified for treating toxoplasmosis, and much of what is discovered in 
Toxoplasma can be readily translatable to close relatives such as Plasmodium. 
 Regulation of proteins by the acetylation of lysine residues has been 
established as a viable drug target for parasitic infections as well as other human 
diseases including cancer. Toxoplasma’s genome encodes several KATs 
responsible for regulating lysine acetylation, several of which have been 
previously characterized by our laboratory. Historically, our laboratory and others 
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have focused on the nuclear role of KATs in regulating transcription by 
acetylating histone tails. However, global acetylation analyses have been 
conducted in several species and revealed that hundreds of diverse proteins are 
acetylated throughout the entire prokaryotic and eukaryotic cell. The current 
challenge is to identify the enzymes responsible for acetylating these proteins 
and how this post-translational modification affects cellular processes.  
 In an attempt to uncover novel KATs in Toxoplasma, we identified a 
homologue of Elp3 (TgElp3) that contains predicted KAT and radical SAM 
domains. Based on evidence in the literature, we sought to characterize 
TgElp3 and hypothesized that it functions as a KAT, acetylating multiple 
substrates, and is essential for parasite viability. After examining the 
sequence of TgElp3 and performing several localization experiments, we 
discovered that TgElp3 contained several unique characteristics including the 
presence of a C-terminal transmembrane domain (TMD) and that it localized to 
the mitochondrion. Therefore, we subsequently hypothesized that the C-
terminal TMD targets TgElp3 to the outer mitochondrial membrane. Our 
hypotheses were examined by testing the following specific aims: 1) identify the 
specific localization of TgElp3 and the role of the TMD in trafficking, 2) determine 
if TgElp3 has KAT activity and identify its substrates, and 3) establish if TgElp3 is 
essential for Toxoplasma tachyzoite survival.  
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II. MATERIALS AND METHODS 
 
A. Tissue culture and parasite maintenance 
Toxoplasma parasites, being obligate intracellular parasites, were 
maintained by serial passage in human foreskin fibroblasts (HFFs). HFFs were 
grown to confluency in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (host medium) 
in a humidified incubator at 37°C with 5% CO2. HFFs were then inoculated with 
parasites and grown in DMEM supplemented with 1% FBS (parasite medium) 
until the parasites completely lysed the host cell monolayer, at which point the 
parasites were transferred to a new flask containing confluent HFFs. When 
necessary, parasite medium was supplemented with the compound Shield-1 
(Cheminpharma cat# CIP-S1-0005), dissolved in 100% ethanol, in order to 
stabilize recombinant proteins fused to a destabilization domain (89). In addition 
to HFFs, an immortalized form of HFFs, HTERT (human telomerase reverse 
transcriptase)-HFFs (ATCC #CRL-4001), were used for serial passage and to 
produce large numbers of parasites. Stocks of host cells and parasite lines were 
stored in liquid nitrogen.  
 There are several strains of Toxoplasma, and the parasites have multiple 
stages (tachyzoite, bradyzoite, and oocyst) in their full life cycle. All studies were 
done using a type I tachyzoite strain of Toxoplasma with an RH background. This 
parasite strain is hypervirulent and reproduces asexually by means of 
endodyogeny, two daughters forming within the mother cell. RHΔhx parasites 
have had the hypoxanthine-xanthine-guanine phosphoribosyl transferase 
(HXGPRT) gene disrupted for drug selection purposes (90). RHΔku80Δhx 
parasites, in addition to disruption of the HXGPRT gene, have a deletion in the 
Ku80 gene in order to promote homologous recombination for efficient plasmid 
integration (91,92).   
 Mycoplasma testing was conducted two to three times a year to check for 
Mycoplasma contamination of cells. The Mycoplasma Plus PCR Primer Set 
(Agilent #302008) was used and the manufacturer’s instructions followed. Briefly, 
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100 µl of medium from culture flasks was boiled, treated with StrataClean resin, 
and used for PCR with Taq. The provided primers can detect most species of 
Mycoplasma. If Mycoplasma was detected, the cells were discarded and new 
stocks thawed. If there was no stock available, the Mycoplasma Removal Agent 
(MP Biomedicals #093050044) was used according to instructions until the 
contamination was eliminated.  
 
B. Toxoplasma and HFF lysate preparation 
 In order to harvest HFFs for downstream applications, they were 
trypsinized and centrifuged at 1,000 x g for 10 min. Pellets were washed in 1X 
phosphate buffered saline (PBS), centrifuged as before, and stored at -80°C until 
needed. Extracellular Toxoplasma parasites were harvested when the host cell 
monolayer had been completely lysed at which point the parasites were filtered 
through a 3 µm polycarbonate filter (Whatman) and centrifuged at 400 x g for 10 
min. The pellet was washed in 1X PBS, centrifuged as before, and stored at -
80°C until needed. 
 To prepare lysates from cells, pellets were resuspended in radio 
immunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 7.9, 150 mM NaCl, 
1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitor 
cocktail) and incubated at 4°C with rocking for 30 min. Lysates were sonicated 
three times for 15 sec each with 30 sec on ice in between sonications. Large 
debris and insoluble material were discarded by centrifuging the lysate at 21,000 
x g for 10 min at 4°C and discarding the pellet. Protein concentrations of cell 
lysates were determined using the DC™ Protein Assay (Bio-Rad #500-0112) 
following the microplate assay protocol. Lysates were used for Western blotting, 
immunoprecipitation, and lysine acetyltransferase assays.  
 
C. Toxoplasma transfection 
 Parasites were transfected with various plasmids in order to ectopically 
express recombinant DNA or to modify the endogenous genome. Because 
Toxoplasma tachyzoites are haploid, making endogenous alterations is 
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straightforward in that only a single locus requires modification. In general, the 
RHΔhx parasite line was used for expression of ectopic constructs whereas 
RHΔku80Δhx parasites were used for endogenous genomic manipulation.    
 Prior to transfection, plasmids were linearized using a restriction site 
downstream of the expression cassette in order to promote integration into the 
genome. Twenty-five to fifty micrograms of DNA was digested overnight with an 
appropriate restriction enzyme.  DNA was purified by adding an equal volume of 
Phenol:Chloroform:Isoamyl Alcohol, mixing vigorously, and centrifuging at 21,000 
x g for 2 min. The top layer containing DNA was transferred to a new Eppendorf 
tube and DNA was precipitated by adding 0.1 volumes of sodium acetate pH 5.2 
and 2.5 volumes of ice cold 100% ethanol and kept at -20°C for several hours. 
The precipitated DNA was pelleted by centrifuging at 21,000 x g for 10 min and 
washed with 500 µl of 70% ethanol and centrifuged at 21,000 x g for 10 min. In a 
laminar flow hood the ethanol was removed and the DNA pellet left to dry. The 
DNA pellet was then suspended in 100 µl of sterile cytomix, a buffer that mimics 
intracellular conditions during transfection (120 mM KCl, 0.15 mM CaCl2, 10 mM 
K2HPO4/KH2PO4 pH 7.6, 25 mM HEPES pH 7.6, 2 mM EDTA, 5 mM MgCl2, 1.2 
mg/ml ATP, and 1.44 mg/ml Glutathion) (93).  
 Parasites were prepared for transfection by filtering extracellular parasites 
through a 3 µm polycarbonate filter (Whatman) and centrifuging at 400 x g for 10 
min. The parasite pellet was resuspended in 10 ml of cytomix and parasites were 
counted using a hemocytometer. After counting, the parasites were centrifuged 
as before and resuspended in cytomix to obtain 2 x 107 parasites per 300 µl. 
Three hundred microliters of parasites was added to the 100 µl of DNA, mixed, 
and transferred to a 2 mm gap electroporation cuvette (Fisher #BTX620). For 
transfection, a BTX ECM 630 electroporator was used and the parasites were 
pulsed with 1.5 kV, 25 ohms, and 25 µF. After electroporation, parasites were left 
to recover for 15 min, split evenly between multiple T-25 cm2 flasks of confluent 
HFFs, and incubated at 37°C with 5% CO2.  
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D. Drug selection 
 Drugs used for selection were added 24 to 48 hrs post-transfection and 
were continued for several passages of the parasites. Different drugs were used 
for selection based on the selection cassette present in the transfected plasmid. 
Plasmids transfected into RHΔhx parasites for ectopic expression contained the 
HXGPRT minigene for selection. RHΔhx parasites, lacking HXGPRT, require 
inosine-monophosphate dehydrogenase (IMPDH) for the synthesis of guanine-
based nucleotides (90,94). These parasites are susceptible to the drug 
mycophenolic acid (MPA) that inhibits IMPDH. However, parasites that have 
integrated a plasmid containing the HXGPRT minigene can now bypass the 
IMPDH pathway and survive in the presence of MPA with the addition of 
xanthine, a guanine nucleotide precursor.  Therefore, 25 µg/ml of MPA and 50 
µg/ml of xanthine were used to select for integration of HXGPRT containing 
plasmids in RHΔhx parasites.  
 Plasmids transfected into the RHΔku80Δhx parasite line contained a 
mutated dihydrofolate reductase-thymidylate synthase (DHFR-TS) minigene 
cassette that renders the recombinant protein resistant to pyrimethamine, a drug 
that kills parasites by inhibiting endogenous DHFR-TS (90). Parasites that have 
integrated the mutated DHFR-TS-containing plasmid are selected for by treating 
with 1 µM pyrimethamine.   
 
E. Cloning by limiting dilution 
 After several rounds of drug selection, limiting dilution was used to isolate 
individual clones from populations of transfected parasites if a clonal population 
was needed. Transfected parasites in each T-25 cm2 flask were counted using a 
hemocytometer and the number of parasites calculated. Parasites were diluted 
1:1,000 in medium and an appropriate volume was transferred to 20 ml of 
medium containing drug in order to obtain a concentration of one parasite per 
well in a 96-well plate containing confluent HFFs. Inoculated plates were left 
undisturbed for 5 to 7 days, at which point the wells were screened for those 
containing a single plaque formed by one original parasite. Several clones were 
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chosen, usually 24 to 48, and transferred to 24-well plates of HFFs. Clones were 
screened for correct construct integration by PCR of genomic DNA and/or 
immunofluorescence assays.   
 
F. Bioinformatics, alignments, and prediction algorithms 
 The primary databases used for gene and protein information and 
BLASTp analyses included the Toxoplasma database (ToxoDB, 
http://toxodb.org) (95), National Center for Biotechnology Information (NCBI, 
http://www.ncbi.nlm.nih.gov) (96), and Eukaryotic Pathogen Database 
(EuPathDB, http://eupathdb.org) (97). In order to identify GNAT domain-
containing proteins in Toxoplasma, the GNAT domain of TgGCN5-B was used as 
the query sequence for BLASTp analysis in ToxoDB. One of the hits, 
TGGT1_305480, we named TgElp3 because of its homology to yeast and human 
Elp3. Protein alignments of Elp3 homologues from Toxoplasma gondii 
(TGGT1_305480), Plasmodium falciparum (XP_001350675.1), Homo sapiens 
(NP_060561.3), and Saccharomyces cerevisiae (NP_015239.1) were performed 
using ClustalW (BioEdit software). Predicted domains of TgElp3 were identified 
using Pfam (http://pfam.sanger.ac.uk) (98) and SMART (http://smart.embl-
heidelberg.de) (99) online algorithms. 
 Upon discovering TgElp3’s unique localization, we used several online 
predictive algorithms including TargetP (http://www.cbs.dtu.dk/services/TargetP/) 
(100), PSORT (http://psort.hgc.jp) (101), and Mitoprot 
(http://ihg.gsf.de/ihg/mitoprot.html) (102) to identify the presence of signal 
sequences and calculate the probability of localization to organelles throughout 
the parasite. We were not able to find a conclusive N-terminal or internal signal 
sequence in TgElp3. However, we did identify the presence of a C-terminal TMD 
using the online tools TMHMM (http://www.cbs.dtu.dk/services/TMHMM/) (103), 
DAS (http://www.sbc.su.se/~miklos/DAS/) (104), and TmPred 
(http://www.ch.embnet.org/software/TMPRED_form.html) (105). These 
algorithms were also used to search for TMDs in other Elp3 homologues.  
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G. Polymerase chain reaction (PCR) 
 All DNA sequences amplified for eventual expression in Toxoplasma were 
amplified using Phusion® High Fidelity DNA Polymerase (Thermo Scientific), 
producing blunt-end PCR products. Fifty microliter reactions were prepared using 
the supplied 5X GC buffer and 10 mM dNTP mix, 10 µM of each primer (forward 
and reverse), approximately 10-100 ng DNA template, and 0.5 µl of the 
Phusion® High Fidelity DNA Polymerase. All primers used for this thesis are 
listed in Table 1. PCRs were placed in an Eppendorf thermocycler and heated 
according to the following protocol:  
1. 98°C for 30 sec 
2. 98°C for 10 sec 
3. 60-70°C for 30 sec 
4. 72°C for 30 sec per 1 kb of amplicon 
5. Repeat steps 2 through 4 for 30-35 cycles 
6. 72°C for 10 min 
7. Hold at 4°C  
 Toxoplasma genomic DNA sequences amplified for screening purposes 
were amplified using GoTaq® Green Master Mix (Promega). To obtain genomic 
DNA from parasite clones for screening, 1.0 ml of freshly lysed extracellular 
parasites was centrifuged at 6,000 rpm for 5 min, resuspended in lysis buffer (50 
mM KCl, 10 mM Tris pH 8.3, 2.5 mM MgCl2, 0.1% SDS, and 20 mg/ml 
ProteinaseK), incubated at 55°C overnight, and heated at 95°C for 10 min. One 
microliter of lysate was used in a 25.5 µl PCR reaction containing 12.5 µl of 
water, 0.25 µl of each primer, and 12.5 µl of GoTaq® Green Master Mix. The 
reactions were heated in a thermocycler according to the following protocol: 
1. 95°C for 2 min 
2. 95°C for 1 min 
3. 60-65°C for 2 min 
4. 72°C for 1 min per 1 kb of amplicon 
5. Repeat steps 2 through 4 for 35 cycles 
6. 72°C for 10 min 
	   26 
7. Hold at 4°C  
 PCR products were separated using gel electrophoresis with a 0.8-1.0% 
agarose gel containing 1 µg/ml ethidium bromide. When DNA needed to be used 
for downstream applications such as cloning, the band corresponding to the 
correct size of DNA desired was excised from the gel. The DNA was then purified 
from the gel slice using the NucleoSpin® gel and PCR clean-up kit (Clontech 
cat# 740609.250) according to the manufacturer’s protocol. DNA was eluted with 
water and stored at -20°C until needed.  
 
Table 1: PCR primers 
Name Sense/ Antisense Sequence 5'-3' Use 
F1 Sense ATGGAACACACTTCCTCTCCTTCTTCTTCC  TgElp3 cloning and 
sequencing R1 Antisense TCACCTACGTCTTCTTACAGCCACGGATGC  
F2 Sense ATGCAGGAGTGGGGTGAGTTCGACC 
TgElp3 sequencing 
F3 Sense TTCCGAGCAGCACTGTAGAACGCGATCTGC 
R2 Antisense GAGAAGTTCTGCTGCCTGCATGAGGCGTCG 
F4 Sense CGTTGAGACCCAAGCTTCCTCTAGAAGAGG 
R3 Antisense ACGCGATTTAAGCGAATCCACGGGTGGACG 
T3 Sense GCAATTAACCCTCACTAAAGG 
T7 Sense TAATACGACTCACTATAGGG 
R4 Antisense CTCGGCTGTGGTTCTGGGATTTCTC  
5' RACE 
R5 Antisense CGAGTGAAGTCCACGGCGGT  
F5 Sense CGAAACGTATTCCAGCTCATCGGCATAC  3' RACE 
F6 Sense GGAATTCGCCACCGTGCTGTACC 
F7 Sense CTGAGGATCCACAGAAAGACAGGAAAAAGC TgElp3 antibody 
R6 Antisense GCGGCCGCTCATTCCGTGAATGC 
F8 Sense ACCGCGGTGGCGGCCGCCGACTTGGAATCGACGCTGTTCG  
5' fragment for 
endoTgElp3HA 
R7 Antisense AGTTCTAGAGCGGCCGCGCACTCCACCTGCGTAAGAGACC  
F9 Sense ACCGCGGTGGCGGCCGCCGACTTGGAATCGACGCTGTTCG  
R8 Antisense CGTAGTCCGGGACGTCGTACGGGTA
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CCTACGTCTTCTTACAGCCACGG  
F10 Sense 
TACCCGTACGACGTCCCGGACTACG
CGTACCCGTACGACGTCCCGGACTA
CGCGTGAGGTGATGAGAAAGAACTA
GTTCC  
R9 Antisense AGTTCTAGAGCGGCCGCGCACTCCACCTGCGTAAGAGACC 
F11 Sense CAGCCTGGCGAAGCTTGCCACCGCTATTTCCACGCACTTCC  3' fragment for 
endoTgElp3HA R10 Antisense CGGTATCGATAAGCTTGGTCGCTGTACGCTAACTCTTGCC 
F12 Sense 
TTCCCTTTTTAGATCTACCATGGCGT
ACCCGTACGACGTCCCGGACTACGC
GGAACACACTTCCTCTCCTTCTTCTT
CC  HATgElp3 
R11 Antisense ATATCATATGAGATCTTCACCTACGTCTTCTTACAGCCACG  
F13 Sense TTCCCTTTTTAGATCTACCATGGAACACACTTCCTCTCC  
TgElp3HA 
R12 Antisense 
ATATCATATGAGATCTTCACGCGTAG
TCCGGGACGTCGTACGGGTACCTAC
GTCTTCTTACAGCCACGG 
F12 Sense 
TTCCCTTTTTAGATCTACCATGGCGT
ACCCGTACGACGTCCCGGACTACGC
GGAACACACTTCCTCTCCTTCTTCTT
CC  HATgElp3ΔTMD 
R13 Antisense 
GTCCCTAGGTCAGATATCCCTACGT
CTTCTGTTCGCCAGCGAGGGGGATT
TCC  
F14 Sense 
ATTCCCTTTTAGATCTAAAATGCATA
TGGTGAGCAAGGGCGAGGAGCTGT
TCACC  YFP 
R14 Antisense CCTTGTAGTCCCTAGGTCAGATATCCTTGTACAGCTCGTCCATGCC  
F15 Sense CTTTTAGATCTCATATGGAACACACTTCCTCTCCTTCTTCTTCC  TgElp3 Nt fragment for 
YFP fusion R15 Antisense CCCTTGCTCACCATATGCGTCAGAACTGTGATCACCAACACC  
F16 Sense GAGCTGTACAAGGATATCACGTACATGGTCAAGGAGTTAGC  TgElp3 Ct fragment for 
YFP fusion R16 Antisense GTCCCTAGGTCAGATATCCCTACGTCTTCTTACAGCCACGG 
F16 Sense GAGCTGTACAAGGATATCACGTACATGGTCAAGGAGTTAGC  TgElp3 Ct ΔTMD 
fragment for YFP fusion R13 Antisense 
GTCCCTAGGTCAGATATCCCTACGT
CTTCTGTTCGCCAGCGAGGGGGATT
TCC  
F17 Sense CTGAGCGGCCGCCGTTCCTCGCTGGTGGGTCTCC  5' fragment for ΔTgElp3 
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R17 Antisense CTAGACTAGTTTCGCTGCCTCTGTCGTCTGC 
F18 Sense CTGAAAGCTTGGTGAGGACTTTGCGGGACTCTTGC  3' fragment for ΔTgElp3 
R18 Antisense TCAGGGGCCCGCGTCGGTATCTGGCTGTGC  
F19 Sense TTCTAAAACCGGAAGAGCTCTACCCGTACGACGTCCCGGACTACGC  
ddHATgElp3 
R19 Antisense TTCCTAGGATCGATGAGCTCTCACCTACGTCTTCTTACAGCCACGG  
F20 Sense TTCCCTTTTTAGATCTAAAATGGCGGGAGTGCAGGTGG  
R11 Antisense ATATCATATGAGATCTTCACCTACGTCTTCTTACAGCCACG  
F21 Sense CCACTCTTACGATGTTAGG 
Screen ΔTgElp3 and 
ΔTgElp3::ddHATgElp3  
clones 
R20 Antisense CCAACAGAAGAGAAGAATCG 
F20 Sense TTCCCTTTTTAGATCTAAAATGGCGGGAGTGCAGGTGG 
R11 Antisense ATATCATATGAGATCTTCACCTACGTCTTCTTACAGCCACG 
F22 Sense GGGTCGACGCCTCATGCAGGC 
R21 Antisense CGTCCAAAAATTTCAGACGG 
F22 Sense GGGTCGACGCCTCATGCAGGC 
R22 Antisense CGAGGTGAGACTGTGTGAAATGCC 
F23 Sense TGGCGGCCGCTCTAGAGGCAAGCTGCCCAGTGGAGAGG WT TMD 5' fragment 
R23 Antisense ATCCACTAGTTCTAGACCTGCCACTGTTCTCCAAAACACC 
F23 Sense TGGCGGCCGCTCTAGAGGCAAGCTGCCCAGTGGAGAGG 
ΔTMD 5' fragment 
R24 Antisense GTTCGCCAGCGAGGGGGATTTCC 
F24 Sense AGAAGACGTAGGTGAGGTGATG 
R23 Antisense ATCCACTAGTTCTAGACCTGCCACTGTTCTCCAAAACACC 
F23 Sense TGGCGGCCGCTCTAGAGGCAAGCTGCCCAGTGGAGAGG 
R25 Antisense CATCACCTCACCTACGTCTTCTGTTCGCCAGCGAGGGGGATTTCC 
F23 Sense TGGCGGCCGCTCTAGAGGCAAGCTGCCCAGTGGAGAGG 
R23 Antisense ATCCACTAGTTCTAGACCTGCCACTGTTCTCCAAAACACC 
F25 Sense CAGCCTGGCGAAGCTTTCTCTTACGCAGGTGGAGTGC WT TMD and ΔTMD 3' 
fragments R26 Antisense CGGTATCGATAAGCTTCCACACGACTGATTATGTCGGATGC 
F26 Sense GGAATTCGCCACCGTGCTGTACC Screen TgElp3 WT TMD 
and ∆TMD clones R27 Antisense GGAACCATTAAGCCGTAGACG 
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H. Reverse transcription (RT)-PCR 
 RT-PCR was used to monitor the absence of endogenous TgElp3 mRNA 
transcript in the ΔTgElp3::ddHATgElp3 parasite lines. Total RNA was isolated by 
harvesting a fully lysed T-25 cm2 flask of each parasite line and filtering the 
parasites through a 3 µm polycarbonate filter followed by centrifugation at 400 x 
g for 10 min. The parasite pellets were washed in PBS, centrifuged as before, 
and stored at -80°C until needed. The RNeasy® Plus mini kit (Qiagen) was used 
to isolate total RNA, and an additional on-column DNA digestion step was 
performed. The Omniscript RT kit (Qiagen) was used to make cDNA twice, once 
using oligo dT primers and once using random primers. The resulting cDNA was 
used directly in PCRs using the GoTaq® Green Master Mix (Promega) as 
described above.  
 
I. Cloning and sequencing TgElp3 
 The predicted TgElp3 gene in type I Toxoplasma tachyzoites is annotated 
as TGGT1_305480 in the online Toxoplasma database ToxoDB (toxodb.org). 
Primers were designed based on the predicted coding sequence (F1 and R1) 
and used to amplify TgElp3 from a RH strain cDNA library. The amplicon was 
ligated into ZeroBlunt®TOPO® vector (Invitrogen) for sequencing. Several 
vector- and gene-specific primers were used to sequence the entire 2,995 bp 
TgElp3 coding sequence, and they are listed in Table 1.   
 Rapid amplification of cDNA ends (RACE) was used to identify the 5’ and 
3’ untranslated regions (UTRs) of TgElp3, and the GeneRacer™ kit (Invitrogen) 
was used according to the manufacturer’s protocol. Primer R4 and nested primer 
R5 were used for amplifying the 5’-UTR and primer F5 and nested primer F6 for 
the 3’-UTR. 
 
J. Generation of TgElp3 antibody 
 In order to generate a TgElp3-specific antibody, we first produced a 120 
amino acid antigen fused to glutathione S-transferase (GST) in bacteria. cDNA 
encoding TgElp3 amino acids 781-900 was amplified with primers F7 and R6 and 
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ligated into the pGEX-4T-3 vector (GE Healthcare cat# 28-9545-52) at restriction 
sites BamHI and NotI. This vector allows for the fusion of GST to the N-terminus 
of the TgElp3 antigen with a thrombin cleavage site for removal of the GST tag. 
The construct was transformed into Rosetta competent cells with ampicillin used 
for selection.  
To produce antigen, bacteria were grown to an OD600 of 0.6 in 500 ml of 
Luria broth containing ampicillin then induced with 1 mM isopropyl β-D-1-
thiogalactopyranoside for 3-4 hrs at 37°C. The bacteria were pelleted, 
resuspended in GST buffer (125 mM Tris-HCl pH 8.0 and 150 mM NaCl) 
supplemented with a protease inhibitor cocktail (Sigma cat# P8465), and 
sonicated 5 times for 15 seconds followed by 30 seconds on ice each time. 
Lysates were then centrifuged at 4°C for 20 mins and the insoluble pellet 
discarded. GST-tagged TgElp3 antigen was purified over glutathione resin 
(Clontech cat# 635607) for 4 hrs at 4°C. GST-bound resin was washed 3 times 
with GST buffer followed by either elution of GST-TgElp3 antigen or cleavage of 
the GST tag by thrombin. GST-tagged TgElp3 antigen was eluted by incubating 
the resin in GST elution buffer (50 mM Tris-HCl pH 8.0 and 10 mM reduced L-
glutathione) for 5 min at 4°C and collecting the supernatant.  In order to cleave 
off the GST tag for antibody production, resin was, instead, incubated with 10 
units of thrombin (Sigma cat# T6884) overnight at 22°C. TgElp3 antigen, cleaved 
from GST, was present in the supernatant and quantified using the Bradford 
assay (Bio-Rad cat# 500-0002). The GST-removed antigen was injected into 
rabbits for polyclonal antibody production (Cocalico Biologicals). Rabbit pre-
immune serum was collected prior to antigen injection, and serum containing 
antibody was collected after three antigen injections, resulting in the antibody 
termed anti-TgElp3. Western blotting was used to test the specificity of anti-
TgElp3 and the lack of contaminants in the pre-immune serum.  
 
K. Endogenously tagging TgElp3  
 The In-Fusion® HD cloning kit (Clontech) was used to clone fragments 
into Toxoplasma expression vectors for all constructs described in this thesis; 
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primer design and cloning were conducted according to the manufacturer’s 
protocol. To endogenously tag TgElp3 at the C-terminus with two hemagglutinin 
(HA) epitopes, TgElp3 genomic 5’ and 3’ fragments were amplified from 
RHΔku80Δhx DNA and inserted into the pDHFR-TS cassette (90) at restriction 
sites NotI and HindIII, respectively. The genomic fragments flanked a selectable 
marker that confers resistance to pyrimethamine to select for parasite clones that 
underwent homologous recombination. The 1,117 bp 5’ genomic fragment was 
constructed using primers F8 and R7 to fuse two fragments consisting of 1) 921 
bp upstream the TgElp3 stop codon amplified by primers F9 and R8 and 2) 139 
bp downstream of the stop codon with a 2X HA tag added upstream of the stop 
codon using primers F10 and R9. The 1,021 bp 3’ genomic fragment was 
amplified using primers F11 and R10. The construct was linearized with NotI and 
transfected into RHΔku80Δhx tachyzoites. The resulting parasite line was termed 
endoTgElp3HA.  
 
L. Ectopically over-expressing tagged TgElp3 
 To stably express ectopic HATgElp3 in parasites, the open reading frame 
was amplified from RHΔhx cDNA with primers F12 and R11 and inserted into a 
Toxoplasma expression vector at the BglII restriction site. This expression vector 
uses the Toxoplasma tubulin promoter and contains an HXGPRT selection 
marker (pHXGPRT:tub) (106). TgElp3HA was made in the same manner with 
primers F13 and R12. HATgElp3ΔTMD was amplified with primers F14 and R13 
and inserted downstream of the tubulin promoter in the pHXGPRT:tub 
expression vector at restriction sites BglII and EcoRV. All three constructs were 
linearized with NotI and transfected into RHΔhx parasites.  
 
M. YFP TgElp3 fusion proteins  
YFP (yellow fluorescent protein) was amplified from pYFP-LIC-HXG 
(kindly provided by Dr. Vern Carruthers) with primers F15 and R14 and inserted 
downstream of the tubulin promoter in pHXGPRT:tub using the BglII and AvrII 
restriction sites. The resulting pHXGPRT:tub-YFP construct contained an NdeI 
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site just upstream and an EcoRV site just downstream of YFP to allow for 
installment of designated TgElp3 fragments. DNA encoding the N-terminal region 
of TgElp3 (amino acids 1-273) was amplified with primers F16 and R15 and 
fused to the N-terminus of YFP using the NdeI restriction site. The C-terminal 
region (amino acids 726-984), amplified by primers F17 and R16, was fused to 
the C-terminus of YFP using the EcoRV restriction site. Removal of the TgElp3 
TMD was achieved by amplifying the C-terminal region with primers F18 and R17 
and inserting the product downstream of YFP using the EcoRV site. YFP fusion 
constructs were transiently transfected into RHΔhx parasites.  
 
N. ΔTgElp3 and ddHATgElp3 constructs  
A TgElp3 knockout construct was designed to facilitate a double crossover 
homologous recombination event to replace the endogenous locus with the 
pyrimethamine-resistant DHFR-TS selectable marker. The 5’ genomic fragment 
encompassing a portion of the TgElp3 5’-UTR and first exon was amplified from 
RHΔku80Δhx DNA with primers F19 and R18 and inserted into the pDHFR-TS 
cassette using restriction sites NotI and SpeI. The 3’ genomic fragment, 
consisting of a portion of the last exon of TgElp3 and 595 bp downstream of the 
stop codon, was amplified with primers F20 and R19 and inserted into this 
plasmid using restriction sites HindIII and ApaI. The construct was linearized with 
NotI and transfected into RH∆ku80∆hx parasites. 
 Recombinant ddHATgElp3 was engineered by first amplifying HATgElp3 
(without the ATG start codon) with primers F21 and R20 and then fusing the 
destabilization domain (dd) by inserting HATgElp3 into the SacI restriction site 
downstream of the dd in a Zero Blunt® TOPO® vector. The dd sequence had 
previously been amplified from pLIC.2XHA-dd::DHFR (kindly provided by Dr. 
Michael White) and ligated into a Zero Blunt® TOPO® vector. ddHATgElp3 was 
then amplified with primers F22 and R21 and inserted into the pHXGPRT:tub 
expression vector using the BglII restriction site. After establishing a clonal 
parasite line expressing ddHATgElp3, the TgElp3 knockout construct was 
transfected and parasite clones were screened by PCR for the presence of 
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ectopic ddHATgElp3 and absence of the endogenous TgElp3 locus. Primers used 
for screening are depicted in Figure 16 and listed in Table 1. 
 
O. TgElp3 WT TMD and ∆TMD constructs 
A plasmid was generated to facilitate homologous recombination to 
remove the DNA encoding the TMD from the genomic locus of TgElp3 (∆TMD). 
In parallel, we made a similar construct that contained the wild-type sequence 
(WT TMD) to use as a control for recombination efficiency. The ~1,700 bp 5’ 
genomic fragment of each construct contained a portion of the last intron, the 
entire last exon with or without the TMD (encoding amino acids 958-980), and 
the 3’ UTR (Figure 19). The 3’ genomic fragment consisted of 1,460 bp 
downstream of the 3’-UTR. The WT TMD 5’ fragment was amplified from 
RHΔku80Δhx genomic DNA with primers F27 and R26. The ∆TMD 5’ fragment 
was amplified using a series of PCRs to piece together sequences upstream and 
downstream of the TMD. PCR-1 and PCR-2 consisted of RHΔku80Δhx genomic 
DNA with primers F28+R27 and F29+R28, respectively. PCR-3 used template 
from PCR-1 and primers F30 and R29. PCR-4 combined the pieces by using 
template from PCR-2 and PCR-3 with primers F31 and R30. The 3’ fragment 
used for both the WT TMD and ∆TMD constructs was amplified from 
RHΔku80Δhx genomic DNA using primers F32 and R31. The 5’ and 3’ fragments 
were inserted into the pDHFR-TS pyrimethamine-resistance cassette using the 
restriction sites XbaI and HindIII, respectively. WT TMD and ∆TMD constructs 
were transfected into RHΔku80Δhx parasites, and 24 clones from each parasite 
line were screened by PCR using the primers shown in Figure 19.    
 
P. SDS-PAGE and Western blotting 
 Toxoplasma lysates were prepared as described in Section II-B. The 
Novex® NuPAGE® SDS-PAGE gel system (Invitrogen) was used for protein 
separation and transfer to nitrocellulose membranes. NuPAGE® LDS sample 
buffer with 5% beta-mercaptoethanol was added to each sample and heated at 
95°C for 10 min prior to loading on 4-12% Bis-Tris pre-cast gels. Gels were 
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electrophoresed in MOPS buffer at 200 V before transfer to a nitrocellulose 
membrane at 30 V for 1-2 hrs. Ponceau S stain was used to assess quality of the 
transfer and equal loading between samples. Membranes were blocked in 4% 
non-fat milk in tris-buffered saline and Tween followed by incubation with primary 
and secondary antibodies that were diluted in blocking buffer. Primary antibodies 
included 1:1,000 rat anti-HA (Roche cat# 11867423001), 1:1,000 rabbit anti-
AcH3 (Active Motif cat# 39139) and 1:2,000 rabbit anti-H3 (Millipore cat#06-755). 
Secondary antibodies used were 1:2,000 goat anti-rat and 1:2,000 goat anti-
rabbit, both conjugated to horseradish peroxidase (HRP) (GE Healthcare cat# 
NA935 and NA934, respectively). Proteins were detected by chemiluminescence 
using the FluorChem E Imager and AlphaView® software (ProteinSimple). 
Densitometry analysis was conducted using ImageJ software. 
 The quality of the TgElp3-specific antibody was tested by Western blotting 
and probing 250 ng of GST-TgElp3 antigen with a 1:10,000 dilution of raw 
antibody-containing serum (anti-TgElp3) or the rabbit pre-immune serum 
followed by 1:2,000 anti-rabbit conjugated to HRP. In addition, 70 µg of parasite 
and HFF lysates were probed with a 1:2,000 dilution of anti-TgElp3 or the pre-
immune serum to determine the specificity of the antibody.    
 
Q. Preparation and Western blotting of mouse brain mitochondria 
 Mouse brain mitochondrial and cytosolic lysates were prepared from 
FVB/NJ (Friend Virus B NIH Jackson) mice and kindly provided by Dr. Nickolay 
Brustovetsky. The mitochondrial fraction was prepared as previously described 
(107) and the cytosolic fraction was prepared by centrifuging brain homogenate 
at 12,000 x g for 10 min followed by a centrifugation of the supernatant at 
100,000 x g for 30 min. The supernatant was used as the cytosolic fraction. 
Western blotting was done following SDS-PAGE separation of 50 µg of each 
lysate. Primary antibodies included 1:1,000 rabbit anti-glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (Cell Signaling cat# 2118), 1:1,000 rabbit 
anti-cytochrome c oxidase subunit IV (COX IV) (Cell Signaling cat# 4850), and 
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1:1,000 rabbit anti-human Elp3 (Active Motif cat# 39949). The secondary 
antibody was goat anti-rabbit conjugated to HRP (GE Healthcare cat# NA934).   
 
R. Immunoprecipitation 
 Parasites expressing HA-tagged forms of TgElp3 and their parental lines, 
typically RHΔhx, were harvested and lysed as described in Section II-B. A total 
protein concentration of 2-4 mg in a 500 µl volume of each parasite lysate was 
used for immunoprecipitation (IP). Lysates were first pre-cleared of materials that 
bind non-specifically to IP beads by incubating for 1-3 hrs at 4°C with 25 µl of 
Protein G beads (Roche cat# 11719416001). The beads had been washed three 
times in lysis buffer before being added to the lysates. Pre-cleared lysates were 
centrifuged at 8,000 rpm for 1 min and the beads discarded. Beads used for IP 
were conjugated to a high-affinity HA antibody (Roche cat# 11815016001) and 
were washed three times in 500 µl of lysis buffer. Fifty microliters of the washed 
anti-HA bead matrix was added to each pre-cleared lysate and incubated 
overnight at 4°C on a rocker. Samples were then centrifuged at 8,000 rpm for 1 
min and the unbound lysate removed. The bead matrix was washed twice in 500 
µl of lysis buffer and once in 500 µl of KAT assay buffer (see below) and used 
directly in in vitro KAT assays (Section II-S).  
 
S. Lysine acetyltransferase (KAT) assays 
 IP beads were used directly in a 30 µl reaction including KAT assay buffer 
(250 mM Tris-HCl pH 8.0, 25% glycerol, 0.5 mM EDTA, 250 mM KCl, 5 mM DTT, 
5 mM PMSF, and 50 mM sodium butyrate), 2 µg histone H3 (Millipore cat# 14-
494), and 2 mM acetyl-CoA (Sigma cat# A2056). The negative control included 
all reagents except beads. Reactions were incubated at 30°C for 1 hr followed by 
the addition of 1X LDS NuPAGE® loading buffer supplemented with 5% beta-
mercaptoethanol and heated at 95°C for 10 min. Western blotting was performed 
as previously described and membranes were probed with 1:1,000 anti-
acetylated H3 (anti-AcH3) followed by 1:2,000 anti-rabbit conjugated to HRP. 
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They were also probed with rat anti-HA to detect TgElp3 that had been 
immunoprecipitated and used as substrate in the KAT assay.  
 In order to test tubulin as a potential substrate of TgElp3, IPs and KAT 
assays were conducted as before except using microtubules as substrate in 
place of histone H3. Tubulin purified from bovine brain was polymerized to form 
microtubules, and the microtubules were stabilized using paclitaxel. The reaction 
to form microtubules contained 1X general tubulin buffer (Cytoskeleton cat# 
BST01-001), 5% glycerol, 1 mM GTP (Cytoskeleton cat# BST06-001), 20 µM 
paclitaxel (Cytoskeleton cat# TXD01), and 3 mg/ml of tubulin (Cytoskeleton cat# 
TL238) and was incubated at 37°C for 45 min. The resulting stable microtubules 
were used directly in an in vitro KAT assay as substrate. Western blot 
membranes of the KAT assay reactions were probed with a 1:5,000 dilution of 
mouse monoclonal anti-acetylated alpha-tubulin (anti-AcTubulin) (Sigma cat# 
T7451) followed by a 1:5,000 dilution of anti-mouse conjugated to HRP (GE 
Healthcare cat# NA931). 
 
T. Immunofluorescence assays 
 Immunofluorescence assays (IFAs) were performed by inoculating 
parasites onto confluent HFF cell monolayers grown on coverslips in 12-well 
plates. Infected HFF monolayers were fixed 16-24 hrs post-infection with 3% 
paraformaldehyde/PBS for 15 min then quenched with 0.1 M glycine/PBS for 5 
min and permeabilized with 0.2% Triton X-100/3% BSA for 10 min. Wells were 
washed with PBS three times between each step. Samples were blocked with 
3% BSA for a minimum of 1 hr and incubated with one or more of the following 
primary antibodies in 3% BSA overnight at 4°C: 1:1,000 rat anti-HA (Roche cat# 
11867423001), 1:10,000 rabbit anti-TgIF2α (108), and 1:2,000 mouse anti-
TgF1B-ATPase (109). Coverslips were washed with PBS three times for 5 min 
each and then incubated with various secondary antibodies conjugated to Alexa 
Fluor 488 and Alexa Fluor 594 (Invitrogen). Coverslips were mounted to slides 
with VectaShield® Mounting Medium containing 4',6-diamidino-2-phenylindole 
(DAPI) (Vector Laboratories cat# H-1200) and visualized on a Nikon Eclipse 80i 
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fluorescent microscope. Image analysis was performed using the Nikon NIS 
Elements AR version 4.00.08 software. 
 MitoTracker® was used as an additional, independent mitochondrial 
marker. Before fixation for IFA analysis, the culture medium was replaced with 
fresh, warm medium containing 100 µM of MitoTracker® Red CMXRos 
(Invitrogen cat# M-7512) and allowed to incubate at 37°C with 5% CO2 for 30 
min. Cells were then washed with PBS and fixed and processed as described 
above.  
 To examine the orientation of TgElp3 in the mitochondrial outer 
membrane, IFAs were conducted using digitonin to selectively permeabilize 
membranes. IFAs were performed in the same manner as described above with 
the exception that samples were incubated for 5 min in either 0%, 0.004%, or 
0.1% digitonin in order to permeabilize cell membranes. Anti-TgIF2α and anti-
TgF1B ATPase were used as cytoplasmic and mitochondrial matrix markers, 
respectively.  
 
U. Immunoelectron microscopy 
 Immunoelectron microscopy processing and analysis were conducted with 
the help of Wandy Beatty at Washington University, St. Louis. Clonal parasites 
stably expressing ectopic HATgElp3 or TgElp3HA along with the parental line 
(RH∆hx) were grown overnight in a T-25 cm2 flask containing confluent HFF 
monolayers. The infected monolayer was washed with PBS, scraped, and 
centrifuged for 10 min at 3,000 x g. Cells were resuspended in fixative containing 
4% paraformaldehyde and 0.05% glutaraldehyde in PBS and incubated on ice for 
1 hr. Samples were then cryo processed and sectioned; 50 nm thick sections 
were used for immunolabeling. To immunolabel sections, they were blocked with 
5% fetal calf serum/5% goat serum in piperazine-N,N’-bis(2-ethanesulfonic acid) 
buffer for 20 min at room temperature. Primary antibody, rat anti-HA, was used at 
a 1:25 dilution in blocking buffer and incubated for 1 hr at room temperature. 
Samples were then incubated for 1 hr in a 1:30 dilution of goat anti-rat secondary 
antibody conjugated to 18 nm colloidal gold (Jackson ImmunoResearch 
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Laboratories, Inc., West Grove, PA) and stained with 5% uranyl acetate/2% 
methyl cellulose. Samples were analyzed on a JEOL 1200 EX transmission 
electron microscope (JEOL USA Inc., Peabody, MA) with an AMT 8 megapixel 
digital camera and AMT version 602 software (Advanced Microscopy 
Techniques, Woburn, MA). 
 
V. Toxoplasma plaque assay 
 Plaque assays were used to assess changes in parasite replication. 
Intracellular parasites were harvested by scraping the host cell monolayer 
infected with Toxoplasma and centrifuging at 400 x g for 10 min. The pellet was 
syringe lysed with a 25-guage needle, and the parasites were filtered using a 3 
µm polycarbonate filter (Whatman). After centrifuging at 400 x g for 10 min, the 
parasites were resuspended in 4 ml of parasite medium and counted using a 
hemocytometer. Each parasite line was diluted in 5 ml of parasite medium to a 
concentration of 5 parasites per microliter. Twelve-well plates containing 
confluent HFFs were inoculated with 100 µl (500 parasites) per well of each 
parasite line and grown in either regular parasite medium, medium supplemented 
with ethanol, or medium supplemented with 250 nM Shield-1. Each treatment 
was conducted in triplicate.  Four hours after inoculation, medium and uninvaded 
parasites were removed and replaced with fresh medium supplemented with the 
same treatments as before, and the cultures were incubated under normal 
conditions (described in section II-A) for 5 days. Cells were then fixed with 100% 
ice-cold methanol for 10 min and stained with crystal violet in order to visualize 
the plaques. Pictures of the plaques in each well were taken using the 
FluorChem E Imager (ProteinSimple), and AlphaView® software (ProteinSimple) 
was used to calculate the area of host cells lysed by the parasites in each well. 
The average was calculated from the three wells for each treatment.  
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III. RESULTS 
 
A. An Elp3 homologue is present in Toxoplasma  
 With evidence indicating the importance of KATs to Toxoplasma growth, 
differentiation, and survival, we searched the online Toxoplasma database for 
uncharacterized KATs and identified a predicted protein that had homology to the 
yeast KAT Elp3. The gene TGGT1_305480, which we have designated TgElp3, 
is located on chromosome IX and contains 9 exons and 8 introns. The database 
predicted the coding sequence of TgElp3 to be 2,955 bp in the type I GT1 strain, 
corresponding to 984 amino acids. We amplified and sequenced the TgElp3 
coding sequence from a type I RH strain cDNA library, verifying the database 
prediction to be correct. In addition, we used rapid amplification of cDNA ends 
(RACE) to identify the 5’- and 3’-UTRs of the TgElp3 transcript and found them to 
be 568 bp and 70 bp, respectively, making the entire TgElp3 mRNA transcript 
1,622 bp in length.  
 TgElp3 is predicted to contain the highly conserved radical S-
adenosylmethionine (SAM) and KAT domains found on all Elp3 proteins from 
archaebacteria to humans (Figure 6A). The critical residues for KAT activity are 
conserved (Figure 6B). Intriguingly, the radical SAM domain in the Toxoplasma 
and Plasmodium Elp3 homologues contains the canonical CxxxCxxC motif 
important for iron-sulfur cluster formation while most other Elp3 homologues 
contain a non-canonical Cx4Cx9Cx2C motif (Figure 6B). Strikingly, TgElp3 also 
harbors a predicted transmembrane domain (TMD) at its extreme C-terminal (Ct) 
end followed by four arginine residues. Further analysis revealed that other 
members of the Apicomplexa phylum, including Plasmodium spp, 
Cryptosporidium spp, Neospora spp, Theileria spp, and Eimeria spp, have this 
unusual Ct TMD on their Elp3 homologues. Another parasitic alveolate, 
Perkinsus marinus, has an Elp3 with a Ct TMD, but free-living alveolates like 
Tetrahymena thermophila do not. The presence of the Ct TMD is also found on a 
limited number of other chromalveolates, including brown algal and water mold 
species. We could not find any eukaryote outside of Chromalveolata in 
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possession of an Elp3 with a Ct TMD, suggesting this feature is restricted to 
select members of this supergroup. 
 
 
Figure 6: Comparison of Elp3 homologues reveals unique and conserved 
features. A) Depiction of Elp3 protein sequences from Toxoplasma gondii 
(TgElp3), Plasmodium falciparum (PfElp3), Homo sapiens (HsElp3), and 
Saccharomyces cerevisiae (ScElp3). SAM = radical S-adenosylmethionine 
(SAM) domain; KAT = lysine acetyltransferase domain; TMD = transmembrane 
domain; aa = amino acids. B) Amino acid alignments of radical SAM and KAT 
domains with similar residues highlighted in light gray and identical residues 
highlighted in black with white letters. In the radical SAM domain alignment, the 
“#” denotes conserved cysteine residues critical for iron-sulfur cluster formation in 
human and yeast homologues (60,61,110) while the asterisks indicate those in 
the Toxoplasma and Plasmodium homologues. In the KAT domain, asterisks 
denote residues previously shown to be important for KAT activity (59,111-113). 
Amino acid number indicated on the right.   
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B. Toxoplasma lacks an Elongator complex 
Elp3 homologues in most species studied to date have been shown to be 
the catalytic subunit in the six-subunit Elongator complex (Elp1-6). A thorough 
bioinformatics survey of the Toxoplasma database and those of other eukaryotic 
pathogens was unable to identify homology to any member of the Elongator 
complex aside from Elp3. The entire sequence of proteins Elp1-Elp6 from both 
yeast and human were used as input sequences for BLASTp analyses in the 
NCBI database, the eukaryotic pathogen database, and each individual database 
of several apicomplexans including Toxoplasma, Plasmodium, and 
Cryptosporidium. In all species examined, Elp3 homologues were identified with 
high bit scores and low E values. WD40 repeats present within Elp2 had 
homology to WD40 containing proteins but no definitive Elp2 homologues were 
identified in any of the apicomplexans. The remaining Elongator proteins had 
little to no homology to apicomplexan proteins. While the Elongator complex is 
highly conserved from yeast to humans, Toxoplasma and other apicomplexans 
appear to lack this complex but have retained the catalytic component, Elp3.   
 
C. TgElp3 protein size and expression  
After confirming the presence of TgElp3 mRNA and establishing the 
length of transcript, we next sought to confirm protein expression and size. This 
experiment was done by adding two HA epitopes (2X HA) just upstream of the 
stop codon of the endogenous TgElp3 genomic locus in order to express TgElp3 
with a double HA tag at its C-terminus. Homologous recombination was used to 
add 2X HA to the 3’ end of the TgElp3 locus in RHΔku80Δhx parasites and 
introduce a mutated form of DHFR-TS to use for selection. A clonal parasite line 
was obtained with correct integration of the construct (endoTgElp3HA), and 
Western blotting with an HA antibody was used to establish protein size and 
relative abundance. We found that TgElp3 is 100 kDa as expected but we also 
detected a band approximately 80 kDa in size, suggesting that TgElp3 may be 
cleaved or degraded (Figure 7). One possibility for the cleavage or degradation 
could be due to the addition of the HA tag near the TMD, resulting in a disruption 
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of protein folding or function. Our results also suggested that TgElp3 is 
expressed in very low abundance, which is in accordance with expression data 
provided in the Toxoplasma database and is consistent with expression of other 
KATs. 
Since TgElp3 is naturally expressed at such a low level, it can be difficult 
to detect and difficult to characterize. Therefore, we also ectopically expressed 
HA-tagged TgElp3 under the tubulin promoter, a constituatively strong promoter. 
Clonal lines were obtained of TgElp3 tagged at both the N-terminus (HATgElp3) 
and C-terminus (TgElp3HA) in RHΔhx parasites. Western blots of TgElp3HA 
showed similar results as endoTgElp3HA with the presence of two bands at sizes 
100 kDa and 80 kDa (Figure 7). Interestingly, even with the tubulin promoter, 
expression levels of TgElp3HA were similar to those seen for endoTgElp3HA. 
Parasites expressing HATgElp3, on the other hand, expressed the ectopic protein 
at very high levels, and a single 100 kDa band was detected by Western blot 
(Figure 7). Results observed for both tagged lines were consistent among 
several aclonal and clonal parasite populations. Combined evidence suggests 
that the parasites do not tolerate the addition of an epitope tag in close proximity 
to the C-terminal TMD. Therefore, we used the HATgElp3 parasite line for the 
majority of our studies.  
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Figure 7: Size of TgElp3. Western blot of 30 µg of lysate from parasites 
expressing ectopic HATgElp3 and 80 µg from parasites expressing ectopic 
TgElp3HA, endogenous TgElp3HA, and the parental line RHΔhx. Blots were 
probed with an anti-HA antibody followed by a goat anti-rat antibody conjugated 
to HRP. 
 
 
D. Attempt to generate a TgElp3-specific antibody  
 In order to study native protein without the use of epitope tags, we 
generated a TgElp3-specific polyclonal antibody in rabbit. We chose a 120 amino 
acid sequence between the KAT domain and the TMD (amino acids 781-900) 
that would serve as a soluble antigen for antibody production. The resulting 
antibody clearly recognized antigen while rabbit pre-immune serum did not 
(Figure 8A). However, when the antibody was used to probe parasite lysates, it 
recognized many proteins as several bands were seen by Western blot (Figure 
8B), and the bands were inconsistent between samples. Attempts to affinity-
purify the antibody were also unsuccessful. Therefore, we concluded that the 
antibody recognizes non-specific products and is not reliable for use in our 
studies.  
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Figure 8: TgElp3-specific antibody. A) Western blot of 250 ng of GST-tagged 
TgElp3 antigen (arrow) probed with a 1:10,000 dilution of either the rabbit pre-
immune serum or the final TgElp3 antibody followed by a 1:2,000 dilution of a 
goat anti-rabbit antibody. B) Western blot of 70 µg of parasite and host cell, HFF, 
lysates probed with a 1:2,000 dilution of either the anti-TgElp3 antibody or the 
rabbit pre-immune serum. Ponceau S stain shows the presence of protein in all 
lanes.   
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E. TgElp3 localizes to the mitochondrion 
 The most well characterized KATs are located in the nucleus and play a 
key role in regulating gene transcription. However, the increasing identification of 
non-nuclear KATs has prompted many to explore the function of these KATs 
outside of the nucleus. Elp3 homologues have been shown to have a role in 
transcription in the nucleus, but in most species, Elp3 is primarily found in the 
cytoplasm. We investigated the localization of TgElp3 by performing 
immunofluorescence assays (IFAs) with parasites expressing HA-tagged forms 
of TgElp3. IFA analysis of intracellular tachyzoites revealed an unexpected 
staining pattern that resembled the parasite’s single mitochondrion organelle, 
which forms a lasso-like structure around the nucleus. HATgElp3 and TgElp3HA 
both co-localized with the mitochondrial matrix protein TgF1B ATPase as well as 
with MitoTracker (Figure 9A-B). The TgF1B ATPase-specific antibody was used 
to visualize the mitochondrion from parasites only whereas MitoTracker infiltrates 
both host cell (HFF) and Toxoplasma mitochondria.  
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Figure 9: TgElp3 localizes to the parasite mitochondrion. IFAs of HATgElp3, 
TgElp3HA, and RHΔhx parasites probed with a rat anti-HA antibody (green) and a 
mouse anti-TgF1B ATPase antibody (red) (A) or MitoTracker (red) (B). Images 
were merged with the DNA stain DAPI (blue), and the white scale bar represents 
5 µm.  
 
 
 For better resolution, immunoelectron microscopy (IEM) was also 
performed using an HA antibody with parasites expressing HATgElp3 and 
TgElp3HA. Virtually all gold particles were found in the mitochondrion with the 
vast majority located at the outer mitochondrial membrane (Figure 10). No gold 
particles were detected in the parental parasites probed with this HA antibody 
(not shown). Our IFA and IEM studies indicated that TgElp3 is targeted almost 
exclusively to the mitochondrion and may reside within the membrane. 
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Figure 10: IEM images of TgElp3 localization. Representative images of 
HATgElp3 and TgElp3HA parasites probed with an anti-HA antibody and an anti-rat 
antibody conjugated to 18 nm gold particles. Gold particles were found almost 
exclusively at the parasite mitochondrial (M) membrane. 
 
 
F. Mitochondrial targeting is mediumted by the C-terminal TMD of TgElp3 
 TgElp3 localization to the mitochondrion was particularly surprising, as 
online predictive algorithms including TargetP and PSORT failed to identify a 
canonical N-terminal or internal mitochondrial signal sequence in TgElp3. To 
identify the mechanism by which TgElp3 is targeted to the mitochondrion, we 
generated a series of YFP fusion proteins (Figure 11A). As shown in Figure 11B, 
YFP alone is located in the parasite cytosol, but its small size allows diffusion into 
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the parasite nucleus as well. N-YFP consisted of the first 273 amino acids of 
TgElp3 (from the start codon to the radical SAM domain) fused to the N-terminus 
of YFP to test if the N-terminal region contained a novel type of mitochondrial 
targeting sequence, which does not appear to be the case (Figure 11B). YFP-C 
consisted of the region downstream of the KAT domain (259 amino acids) fused 
to the C-terminus of YFP and demonstrated that the C-terminal region and TMD 
are involved in mitochondrial localization. A third construct, N-YFP-C, included 
both N- and C-terminal TgElp3 fragments flanking YFP (lacking the radical SAM 
and KAT domains) and also localized to the parasite mitochondrion. Together, 
these data show that the C-terminal portion of TgElp3 is necessary and sufficient 
for mitochondrial localization, with the N-terminal sequence having no role in 
protein targeting to this organelle. Since this C-terminal fragment contains the 
TMD, we made an additional YFP fusion protein with the TMD deleted. 
Additionally, we stably expressed an ectopic form of HATgElp3 lacking the TMD 
(HATgElp3ΔTMD). With the TMD removed, TgElp3 is no longer targeted to the 
mitochondrion but instead appears to be localized at the parasite’s periphery for 
reasons that remain unknown (Figure 11B). The results consistently demonstrate 
that TgElp3 is unable to localize to the mitochondrion without the TMD. 
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Figure 11: The unique C-terminal TMD of TgElp3 targets the protein to the 
mitochondrion. A) Diagram of constructs used to map the sequence required for 
TgElp3 localization. YFP = yellow fluorescent protein; N = portion of TgElp3 N-
terminal of the radical SAM domain (amino acids 1-273); C = portion of TgElp3 
C-terminal of the KAT domain (amino acids 726-984). B) IFAs of parasites 
expressing the proteins shown in (A). YFP fusion proteins are shown in green; an 
anti-HA antibody was used to detect HATgElp3ΔTMD (green); TgF1B ATPase was 
used as a mitochondrion marker (red). Images were merged with the DNA stain 
DAPI (blue), and the white scale bar represents 5 µm. 
 
 
G. TgElp3 is a tail-anchored outer mitochondrial membrane protein 
 Immediumtely downstream of the TgElp3 TMD is a string of four arginine 
residues. In other eukaryotic species, a C-terminal TMD followed by several 
positively charged residues is sufficient for targeting a protein and inserting it into 
the outer mitochondrial membrane. These proteins are referred to as tail-
anchored and, while the precise mechanism of mitochondrial membrane insertion 
is still unclear, mutational analyses have shown that the TMD sequence serves 
as a mitochondrial targeting signal (114,115). Tail-anchored proteins are often 
inserted in the outer mitochondrial membrane by the C-terminal TMD such that a 
short C-terminal tail faces the inner membrane space and everything upstream of 
the TMD resides in the cytosol (116). To determine the orientation of TgElp3 in 
the mitochondrial membrane, we selectively permeabilized membranes of 
parasites expressing HATgElp3 and TgElp3HA with digitonin prior to IFA analyses. 
Treatment with 0.004% digitonin permeabilized only the plasma membrane of 
Toxoplasma; while a cytoplasmic marker (TgIF2α) was detectable, the 
mitochondrial matrix protein (TgF1B ATPase) was not (Figure 12). Exposure to 
0.1% digitonin permeabilized the plasma membrane as well as the outer 
mitochondrial membrane, but the inner mitochondrial membrane remained 
largely intact. As a result, the mitochondrial matrix marker TgF1B ATPase was 
only partially detectable with 0.1% digitonin but was fully visible when 0.2% Triton 
X-100 was used to permeabilize all membranes. When only the plasma 
membrane was permeabilized, HATgElp3 was recognized but TgElp3HA was not. 
However, TgElp3HA was visible once the mitochondrial outer membrane had 
been permeabilized. These results indicate that TgElp3 is anchored in the outer 
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mitochondrial membrane with the N-terminus facing the cytoplasm and the short 
C-terminus located within the inner membrane space. Such an orientation leaves 
TgElp3 capable of enzymatically acting on cytosolic proteins, proteins associated 
with the mitochondrial surface, or proteins targeted for translocation into the 
mitochondrion.   
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Figure 12: Digitonin selective permeabilization determines TgElp3 orientation. 
HATgElp3 and TgElp3HA expressing parasites were used to visualize the N- and 
C-termini of TgElp3 (green), respectively, while parental RHΔhx parasites were 
used to establish the degree of membrane permeabilization. Detection of 
cytoplasmic TgIF2α (green) and mitochondrial matrix protein TgF1B ATPase 
(red) confirmed permeabilization of Toxoplasma plasma membrane and both 
mitochondrial membranes, respectively. IFAs were performed using indicated 
concentrations of digitonin or Triton X-100 for permeabilization as described in 
the results. 
 
 
H. Elp3 localization to the mitochondria of mammalian cells 
 The localization of TgElp3 to the parasite mitochondrion is contingent 
upon the C-terminal TMD. Elp3 homologues in the vast majority of other species 
do not contain a TMD, but there has been a report showing human Elp3 co-
localizing with the mitochondrial marker MitoTracker by IFA in HeLa cells (117). 
We examined whether mitochondrial Elp3 was unique to Toxoplasma by 
performing Western blots on fractions from mouse brain. As shown in Figure 13, 
a shortened form of Elp3 (~49 kDa) is present in the mitochondrial fraction from 
mouse brain while only the full-length form of Elp3 (62 kDa) is in the cytosolic 
fraction. These results suggest that localization of Elp3 to mitochondria has been 
conserved throughout evolution. 
 
 
Figure 13: Mouse Elp3 present in brain mitochondria. Western blot of Elp3 in 
mitochondrial (M) and cytoplasmic (C) fractions purified from mouse brain. 
Mouse Elp3 is detected at its full-length form (62 kDa) in the cytoplasmic fraction 
and a shorter form (~49 kDa) in the mitochondrial fraction. GAPDH and COX IV 
were used as cytoplasmic and mitochondrial markers, respectively. 
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I. TgElp3 KAT activity and potential substrates 
 Elp3 homologues have been shown to acetylate histones, with a 
preference for histone H3 in vivo, and alpha-tubulin (63,70). We first tested if 
TgElp3 has KAT activity by performing an in vitro KAT assay. This assay tests 
the ability of a protein to transfer an acetyl group from acetyl-CoA to a lysine 
residue on a substrate. Histone H3 was used as substrate because of the high 
number of lysine residues that are amenable to acetylation. Bona-fide KATs 
usually have the ability to acetylate H3 in vitro even if H3 is not an in vivo 
substrate. Recombinant HATgElp3 was isolated from parasite lysate using IP with 
anti-HA conjugated beads (Figure 14A) and used directly in a KAT assay with 
acetyl-CoA and human histone H3. The same protocol was followed using 
RHΔhx lysate, containing no HA epitope, in order to comfirm that the IP alone did 
not contribute to histone acetylation. A negative control was also included that 
contained all KAT assay reagents except IP beads. Western blot analysis with 
anti-acetylated H3 detected H3 acetylation only in the presence of HATgElp3 
(Figure 14A), indicating that TgElp3 has KAT activity.  
 
 
Figure 14: TgElp3 acetylates H3 in vitro. A) Left panel: Western blot (WB) probed 
with an anti-HA antibody following immunoprecipitation (IP) of HATgElp3 and 
RHΔhx lysates over anti-HA conjugated beads. IP samples were used in an in 
vitro KAT assay with histone H3 substrate and acetyl-CoA. Right panel: Western 
blot of the KAT assay reaction probed with an anti-acetylated H3 (α-AcH3) 
antibody. Acetylated H3 was detected in KAT assays containing HATgElp3 but not 
in the IP control (RHΔhx) or KAT assay negative control that contained all KAT 
assay reagents except IP beads (Neg.). B) Western blot of 30 µg of HATgElp3 
and RHΔhx lysates probed with α-AcH3 and α-H3 antibodies. Numbers below 
the blot indicate the ratio of AcH3 compared to AcH3 in RHΔhx parasite lysate. 
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 Our KAT assay results showed that TgElp3 can acetylate histone H3 in 
vitro, so we next investigated H3 acetylation in vivo. Using lysate from the 
parasite line over-expressing HATgElp3, we looked for changes in global histone 
H3 acetylation by probing for acetylated H3. The same level of acetylated H3 
was detected in lysate from HATgElp3 and the parental line, suggesting that over-
expression of TgElp3 does not increase H3 acetylation (Figure 14B).  
 In a suprising study published by Creppe et al (70), Elp3 was shown for 
the first time to acetylate alpha-tubulin in mouse cortical neurons and human cell 
lines. This study, as well as others, also determined that microtubules serve as 
better substrates of Elp3 than monomeric or dimeric alpha-tubulin (71). 
Therefore, we used the in vitro KAT assay to determine if TgElp3 acetylated 
tubulin. The KAT assay was conducted in the same manner as before except 
microtubules, polymerized from bovine brain tubulin, were used as the substrate. 
A caveat to using bovine brain tubulin is that it is already partially acetylated. In 
our study we would predict an increase in acetylated tubulin compared to the two 
controls, RHΔhx and the negative control, if tubulin serves as a substrate for 
TgElp3. However, no change in tubulin acetylation was detected when HATgElp3 
was present (Figure 15A), suggesting that microtubules are not a primary target 
of TgElp3. We also examined in vivo tubulin acetylation by Western blot in 
parasites over-expressing HATgElp3. Again, we saw no significant difference 
compared to the parental line, RHΔhx (Figure 15B).  
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Figure 15: Tubulin is likely not a primary substrate of TgElp3. A) Western blot of 
in vitro KAT assay probed with an α-acetylated tubulin (AcTubulin) antibody. 
Acetylated tubulin is detected in all samples but is not increased in the presence 
of HATgElp3 compared to the IP control, RHΔhx, or the KAT assay negative 
control containing all reagents except IP beads (Neg.). B) Western blot of 30 µg 
of HATgElp3 and RHΔhx lysates probed with an α-AcTubulin antibody and an α-
H3 antibody as a loading control. Numbers below the blot indicate the ratio of 
acetylated tubulin compared to acetylated tubulin in RHΔhx parasites. 
 
 
 These results do not definitively prove that H3 and/or tubulin are not 
substrates of TgElp3 because of several caveats. For example, if TgElp3 
requires co-factors or additional proteins in order to function, the stoichiometric 
ratio could prevent an increase in TgElp3 function as a result of an increase in 
TgElp3 protein. Also, because H3 and tubulin are naturally highly acetylated, 
minor changes in acetylation may not be detected by Western blot. However, our 
localization studies also suggest that H3 and tubulin are not primary substrates of 
TgElp3. After our discovery that TgElp3 localizes almost exclusively at the outer 
mitochondrial membrane, we hypothesized that targets of TgElp3 would reside 
near or within the mitochondrion. Our laboratory’s recent analysis of the 
Toxoplasma acetylome identified several acetylated mitochondrial proteins 
including porin, which is an integral outer membrane protein and highly 
acetylated (54,56). Future studies will investigate porin and other mitochondrial 
or mitochondrial-associated proteins as potential substrates of TgElp3.  
 
J. TgElp3 is essential for parasite survival 
 To provide insight into the role of TgElp3 in parasite physiology, we 
designed experiments to knockout the genomic locus. Despite several attempts 
to generate a TgElp3 knockout by replacing the genomic locus with a selectable 
marker in RHΔku80Δhx parasites (Figure 16A), we were unable to obtain viable 
clones, suggesting that TgElp3 is essential for parasite survival (Figure 16B). We 
were, however, able to knockout the locus in transgenic parasites expressing 
ectopic TgElp3 fused to a destabilization domain (ddHATgElp3), which targets the 
fusion protein for degradation unless stabilized by adding Shield-1 to the culture 
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(Figure 16A-C) (89,118). We were unable to obtain a TgElp3 knockout in 
RHΔku80Δhx parasites after screening 60 clones from 11 independent 
populations. However, we were able to knockout the TgElp3 genomic locus at a 
high frequency (58%) in parasites expressing ectopic ddHATgElp3. Both PCR of 
genomic DNA and RT-PCR verified the absence of endogenous TgElp3 in three 
independent knockout clones (Figure 16B-C). We conclude that the TgElp3 
genomic locus is amenable to homologous recombination, but cannot be 
displaced unless a second copy is present, supporting the idea that TgElp3 is 
essential in tachyzoites. 
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Figure 16: Knockout of TgElp3 genomic locus is only possible if ectopic TgElp3 is 
present.  A) Diagrams of TgElp3 genomic locus, constructs, and mRNA including 
primers for screening clones. In the top panel black, gray, and striped bars 
represent exons, introns, and UTRs, respectively. The TgElp3 knockout construct 
uses homologous recombination to replace the genomic locus with a mutated 
form of dihydrofolate reductase-thymidylate synthase (DHFR-TS*) to confer 
pyrimethamine resistance for selection. The middle diagram depicts the construct 
used to express an ectopic copy of TgElp3 tagged at the N-terminus with the 
destabilization domain (dd) and HA epitope containing the tubulin 5’-UTR and 
DHFR-TS 3’-UTR. HXGPRT was used for selection. The bottom panel shows the 
TgElp3 endogenous and ectopic mRNA transcripts with white lines representing 
removed introns. B) Genomic PCR of TgElp3 knockout attempts before and after 
introduction of ectopic ddHATgElp3. The first panel shows PCR amplifications from 
genomic DNA of 8 representative clones (out of 60 total), confirming that the 
TgElp3 locus was not replaced when a TgElp3 knockout was attempted. The 
second panel shows that several knockout clones were obtained when ectopic 
ddHATgElp3 was present, which is shown as the ~3.0 kb band in the bottom gel. 
The ”+” denotes TgElp3 knockout clones, three of which (1E4, 2D5, and 3A12) 
were selected for further analysis by RT-PCR. C) RT-PCR was used to confirm 
the absence of endogenous TgElp3 mRNA in the ΔTgElp3::ddHATgElp3 clones 
and the presence of ectopic ddHATgElp3 mRNA. RHΔku80Δhx served as the 
parental line for ddHATgElp3, and ddHATgElp3 served as the parental line for 
ΔTgElp3::ddHATgElp3. Primer pairs used for PCR screening are located to the 
right of the gel images. Markers are present in the first lane of each gel image 
and negative controls (Neg. control) contain all PCR reagents except DNA 
template. 
 
 
K. Regulation of TgElp3 by an inducible destabilization domain  
 We next wanted to use the ΔTgElp3:: ddHATgElp3 parasite line (clone 
3A12) in order to study the effects of TgElp3 down-regulation. This parasite line 
is normally grown in the presence of Shield-1 in order to express ectopic 
ddHATgElp3 in the absence of endogenous TgElp3. The destabilization domain 
renders the ectopic copy of TgElp3 highly unstable, and it is quickly degraded. 
However, when the destabilization domain ligand Shield-1 is added, it binds and 
stabilizes the protein, allowing ddHATgElp3 to accumulate in the cell. Removing 
Shield-1 significantly reduces the amount of ectopic protein in ΔTgElp3:: 
ddHATgElp3 parasites and the parental line, ddHATgElp3 (Figure 17A-B), and would 
be expected to result in a phenotype consistent with the down-regulation of 
TgElp3. We assessed the phenotype of ΔTgElp3:: ddHATgElp3 parasites in the 
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presence and absence of 250 nM Shield-1 using the plaque assay as a measure 
of parasite replication. In addition, we examined the parental line ddHATgElp3 and 
the original parental “wild-type” parasites (RHΔku80Δhx). Unexpectedly, all three 
parasite lines grew similarly in the presence of Shield-1 and those expressing 
recombinant TgElp3 appeared to grow better than “wild-type” parasites in the 
absence of Shield-1 (Figure 18). 
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Figure 17: Regulation of TgElp3 using a destabilization domain. A) Western blot 
of lysates from ΔTgElp3:: ddHATgElp3 parasites and the parental lines ddHATgElp3 
and RHΔku80Δhx that were grown in the absence (-) or presence (+) of 250 nM 
Shield-1. Blots were probed with a rat anti-HA antibody to detect ectopic TgElp3 
or a rabbit anti-TgIF2α antibody. B) IFA images depicting expression of ectopic 
TgElp3 in the absence (-) or presence (+) of 250 nM Shield-1. An anti-HA 
antibody (green) was used to detect ectopic TgElp3 and was merged with DAPI 
(blue). 
 
 
 
 
 
Figure 18: ΔTgElp3:: ddHATgElp3 parasites do not show a growth defect. Plaque 
assays of ΔTgElp3:: ddHATgElp3 parasites and the parental lines, ddHATgElp3 and 
RHΔku80Δhx, were conducted using the following treatments: none, vehicle, or 
250 nM Shield-1. Parasites were grown in 12-well plates of HFFs for 5 days with 
the respective treatment and the average area of lysed cells was calculated (a.u. 
= arbitrary units). Plaques can be seen in the bottom panels showing 
representative wells for each treatment. The graph shows data from one 
independent experiment (n=1). 
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The observed results are likely based on the fact that Toxoplasma only 
needs a small amount of TgElp3 in order to function normally. As seen in Figure 
17, residual ddHATgElp3 is present even in the absence of Shield-1. These results 
may, in part, be due to an inherent leakiness in the destabilization domain 
approach. However, over-expression of ddHATgElp3 using the strong tubulin 
promoter may also result in an abundance of protein that is not fully degraded in 
the absence of Shield-1. Our current strategy for studying TgElp3 down-
regulation focuses on a similar approach, using the endogenous promoter and 
UTRs of TgElp3 and targeting the construct to a specific locus in the genome. 
This approach should result in a more tightly regulated system and provide a 
more accurate TgElp3 down-regulated phenotype. 
 
L. Mitochondrial localization of TgElp3 is essential 
 As an alternative approach to address the importance of TgElp3, we 
investigated if parasites could survive when TgElp3 is expressed but not able to 
localize to the outer mitochondrial membrane by deleting the TMD (ΔTMD) from 
the endogenous locus (Figure 19A). As a control, we replaced the endogenous 
TMD with a wild-type TMD sequence (WT TMD) to confirm that integration of our 
construct did not produce an artifact. Recombination frequency was ~70% 
(17/24) when the WT TMD construct was used, but we were not able to isolate 
any viable parasites when the ΔTMD construct was used. Figure 19B shows five 
representative clones from each parasite line – five positive WT TMD clones and 
five negative ΔTMD clones. These results suggest that localization of TgElp3 to 
the outer mitochondrial membrane is essential for parasite viability. 
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Figure 19: Deletion of TgElp3 TMD is lethal. A) Schematic of endogenous TgElp3 
genomic locus with integration of WT TMD and ΔTMD. Two thick black lines 
indicate the regions used for homologous recombination. Primers used to screen 
for the correct integration event are shown. B) PCRs of genomic DNA of WT 
TMD and ΔTMD parasite clones. Five representative clones of each are shown 
with (+) indicating integration and (-) indicating no integration. RHΔku80Δhx was 
the parental line. The primer pair and expected sizes are located to the right of 
the gel image.   
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IV. DISCUSSION  
 This thesis describes the first characterization of the Elongator complex 
subunit Elp3 in an apicomplexan species. TgElp3 contains unique characteristics 
including the presence of a C-terminal TMD and a mitochondrial localization. We 
determined that the TMD is necessary and sufficient for targeting TgElp3 to the 
outer mitochondrial membrane. Importantly, TgElp3 is the first mitochondrial-
localized KAT identified and we found this localization to be conserved in a 
higher eukaryotic species. We also identified TgElp3 as a functional KAT that can 
acetylate histone H3 in vitro. While the substrates and functions of TgElp3 have 
yet to be identified, we established TgElp3 is essential for parasite viability and 
that its critical function requires the presence of the C-terminal TMD.   
 
A. Toxoplasma lacks an Elongator complex but possesses a unique Elp3 
homologue   
The six-subunit Elongator complex is conserved in yeast, plants, and 
animals, and it appears that the assembly and function of the complex relies on 
the presence of all six subunits. Nearly identical phenotypes are observed in 
yeast, C. elegans and plants when any of the six proteins is deleted 
(58,76,77,119-122); for example, all Elongator mutants in yeast have a delayed 
growth phenotype when introduced to stresses such as changes in carbon 
source or temperature. Elp3 is considered the catalytic subunit of the complex 
while the other proteins are suggested to be critical for assembly, integrity, 
scaffolding, and docking for interacting proteins (123). Surprisingly, Elp3 is the 
only component of the Elongator complex to exhibit convincing homology to a 
protein found in Toxoplasma and other apicomplexans. The presence of Elp3 in 
protists and other ancestral eukaryotes demonstrates the evolutionary 
importance of this protein but the lack of homology to the other Elongator 
complex members suggests that Elp3 may have acquired additional functions in 
other species.  
In addition to the apparent lack of an Elongator complex in Toxoplasma, 
the TgElp3 enzyme has unique characteristics. The protein is much larger than 
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its yeast, plant, and human counterparts and contains little to no homology 
outside of the two conserved radical SAM and KAT domains, which have 53-56% 
and 53-54% similarities, respecitvely. In addition, TgElp3 contains a unique C-
terminal TMD not present in any Elp3 homologue previously characterized. 
TgElp3 is most closely related to other apicomplexan homologues, which also 
possess a C-terminal TMD. However, the close relative Tetrahymena, a free-
living protist, does not have this domain. Interestingly, outside of the 
Apicomplexa phylum, only a small number of other chromalveolates appear to 
have the C-terminal TMD. Why only a select few species contain this TMD in a 
protein that is conserved throughout every species is unclear. 
A key motif within the radical SAM domain is also different in TgElp3 
compared to homologues previously studied. The first step in all reactions 
involving the radical SAM domain is reduction of the iron-sulfur cluster formed by 
three or four key cysteine residues in the domain. Yeast and human Elp3 
homologues contain a non-canonical Cx4Cx9Cx2C motif, and mutation of these 
cysteines to alanines recapitulates an Elp3 knockout phenotype in yeast (60). 
Interestingly, TgElp3 and several other predicted TMD-containing Elp3 
homologues, including those in apicomplexan species, possess the more 
traditional radical SAM motif (CxxxCxxC) while Elp3 homologues lacking the C-
terminal TMD have a non-canonical motif. Radical SAM domains can participate 
in a number of catalytic reactions and while the function of this domain in Elp3 
orthologues is not clear, it has been implicated in DNA demethylation in zygotes 
(62). However, this function seems unlikely in Toxoplasma given that the 
parasites apparently lack or have little DNA methylation (124). Further 
investigation is necessary to determine if a connection exists between the 
presence of a C-terminal TMD and the function of the radical SAM domain based 
on its cysteine motif.  
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B. TgElp3 is the first KAT identified within the outer mitochondrial 
membrane 
Our studies uncovered the first known acetyltransferase localized to the 
outer mitochondrial membrane in any species. Using IFAs with mitochondrial 
markers, we discovered the unique mitochondrial localization of TgElp3. These 
results were confirmed by IEM, its higher resolution able to pinpoint the 
localization to the mitochondrial membrane. Additional imaging experiments 
using selective membrane permeabilization revealed that TgElp3 is anchored in 
the outer mitochondrial membrane with its catalytic domains oriented towards the 
cytosol (Figure 20). Elp3 homologues examined to date have been portrayed as 
primarily located in the cytoplasm although one study did show a co-localization 
of Elp3 with mitochondria in HeLa cancer cells (117). In addition, several other 
studies showing cytoplasmic localization of Elp3 did not perform co-localization 
experiments or use high-resolution imaging. Elp3 often shows a somewhat 
punctate localization that, if examined more closely, may partially co-localize with 
mitochondria. To determine if Elp3 could be found in the mitochondria of other 
cells, we examined mitochondria purified from mouse brain by Western blot and 
found a shorter form of Elp3 (~49 kDa compared to the normal 62 kDa mouse 
Elp3) present in the mitochondria. Based on our results, we propose that we 
have uncovered a novel localization of Elp3 that is conserved in other species 
and should be examined more closely in other cell types.  
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Figure 20: Depiction of TgElp3 anchored in the outer mitochondrial membrane. 
TgElp3 contains a C-terminal TMD (orange) that anchors TgElp3 in the outer 
mitochondrial membrane such that its catalytic domains, radical SAM (blue) and 
KAT (green), reside in the cytosol and the C-terminal tail is in the intermembrane 
space (IMS).   
 
 
The identification of TgElp3 as a mitochondrial KAT is a crucial discovery 
in the field of protein lysine acetylation. For years, it has been evident that 
mitochondrial proteins are acetylated, and acetylome studies revealed that a 
large proportion of acetylated proteins are in the mitochondria (49,55). In search 
of the enzymes regulating this acetylation, several mitochondrial KDACs were 
identified (SIRT3, SIRT4, and SIRT5). SIRT3, in particular, was found to be 
essential for mitochondrial protein deacetylation and critical for metabolism and 
stress reponse (125-128). However, a mitochondrial KAT remained elusive. Prior 
to our studies, only one report suggested the presence of a KAT-like protein in 
this organelle. The prokaryotic-like 125 amino acid protein named GCN5L1 
[GCN5 (general control of amino acid synthesis 5)-like 1] was enriched in the 
mitochondria of HepG2 (Human hepatocellular liver carcinoma) cells and mouse 
brain (129). While GCN5L1 possesses a conserved acetyl-CoA binding region, it 
does not contain a KAT domain. Data did not show a direct acetylation of 
mitochondrial proteins by GCN5L1 in vivo but indicated that it does affect overall 
mitochondrial acetylation. In addition, in vitro enzymatic assays required the 
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presence of mitochondrial extract with GCN5L1 in order to achieve significant 
acetylation of the substrate. Therefore, GCN5L1 may serve as a cofactor, instead 
of a true KAT, in a mitochondrial acetylation mechanism. We have shown that 
TgElp3 is a functional KAT that is targeted to the mitochondrion, albeit its 
catalytic domains face the cytosol. Our studies place Elp3 as an attractive 
candidate KAT involved in regulating mitochondrial functions. 
 
C. The C-terminal TMD is necessary and sufficient for targeting TgElp3 to 
the mitochondrion 
The mitochondrial localization of TgElp3 was particularly surprising since 
we failed to identify a classic N-terminal or internal mitochondrial signal 
sequence. After investigating the targeting mechanism of TgElp3 using a series 
of YFP fusion proteins, we determined that the C-terminus (downstream of the 
radical SAM and KAT domains) was critical for its mitochondrial localization while 
the N-terminal region of TgElp3 (upstream of the domains) was not. In fact, the 
23 amino acid TMD located at the extreme C-terminus was both necessary and 
sufficient to target TgElp3 to the outer mitochondrial membrane.  
Whereas mitochondrial matrix proteins are targeted and inserted in the 
mitochondria via their N-terminal signal sequence, outer mitochondrial 
membrane proteins are targeted to the mitochondria based on their TMD and 
residues surrounding this domain (114,115). Four types of proteins are generally 
inserted into the outer mitochondrial membrane, those containing a single TMD 
at their N-terminus, those with a C-terminal TMD, those with two TMDs and those 
containing multiple β-strands, forming pores or channels through the membrane 
(130,131). Proteins such as TgElp3 that have a C-terminal TMD inserted into the 
outer mitochondrial membrane are often referred to as tail-anchored proteins. 
The mechanism for how these proteins are inserted into the membrane remains 
poorly understood but the sequences necessary for targeting have been studied 
in depth.  
Tail-anchored proteins are targeted to cellular membranes based on the 
length and hydrophobicity of the C-terminal TMD as well as the presence of 
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positively charged residues surrounding the TMD. Several studies have 
investigated how changes in these properties can redirect a protein to target 
different membranes such as those of the ER or mitochondria. Tail-anchored 
proteins are generally targeted to the mitochondria when the TMD is relatively 
short (approximately 20 amino acids) with a moderate hydrophobicity followed 
immediumtely by several positively charged residues (115). The C-terminus of 
TgElp3 contains these characteristic features including the presence of four 
arginines directly downstream of the TMD.  
Another characteristic thought to influence the targeting of a tail-anchored 
protein is the lipid composition of the membrane. Membranes are made up of 
different proportions of the varying kinds of lipids, giving each membrane a “lipid 
signature”. For example, ergosterol, which increases a membrane’s rigidity, is 
more abundant in the ER membrane than the outer mitochondrial membrane. It 
has been demonstrated that when the ergosterol content is lowered in the ER, 
mitochondrial tail-anchored proteins can be targeted to the ER (132). Loss of the 
TMD in TgElp3 prevents its mitochondrial localization, but with the four arginine 
residues remaining, the protein can be found at the parasite periphery (Figure 
11B). The presence of these positively charged residues likely tethers TgElp3 to 
the plasma membrane, a membrane whose lipid content may be favored by 
TgElp3 when the TMD is absent.  
 
D. Elp3 likely has novel substrates in Toxoplasma 
 Originally, Elp3 was identified as a KAT that acetylated histones, 
preferentially targeting histone H3, and several studies have confirmed histones 
as in vitro and in vivo substrates (59,63,66,69). However, with the realization that 
Elp3 was localized predominantly outside of the nuclear compartment, it was 
proposed that Elp3 targets additional substrates. In support of this idea, alpha-
tubulin was discovered to be acetylated by Elp3 in mouse and human cells (70). 
Several years later, another study found bruchpilot, a cytoskeleton-like protein 
present in the active zone of neurons in Drosophila, to be acetylated by Elp3 
(133). Since Toxoplasma does not have a bruchpilot homologue, we tested both 
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histone H3 and alpha-tubulin as potential substrates of TgElp3. As expected, 
TgElp3 was able to acetylate histone H3 in an in vitro assay (Figure 14A). 
Containing a large number of acetylatable lysines, H3 can be acetylated by most 
functional KATs in vitro regardless of whether it serves as a natural substrate in 
vivo. However, we did not find evidence that TgElp3 acetylated H3 in vivo. Nor 
did our data suggest alpha-tubulin was a primary target of TgElp3. TgElp3 did not 
co-localize with either target, and the potential substrates did not show an 
increase in acetylation when TgElp3 was over-expressed. 
Unfortunately, the experiments used to test if H3 and/or alpha-tubulin are 
substrates of TgElp3 had several caveats and could not definitively prove that 
TgElp3 does not acetylate them in vivo. Additional experiments could be 
performed to obtain more conclusive results. However, our localization data is 
consistent with these findings and suggests that TgElp3 may acetylate novel 
targets. Hundreds of cytosolic and mitochondrial proteins have been detected as 
lysine acetylated in many species including Toxoplasma. The positioning of 
TgElp3 on the cytosolic side of the mitochondrion makes it accessible to both 
cytosolic substrates and mitochondrial substrates, including outer mitochondrial 
membrane proteins or those destined for transport into the organelle. Acetylomic 
analyses of tachyzoites identified both outer mitochondrial membrane proteins, 
such as the heavily acetylated porin, as well as mitochondrial matrix proteins as 
being targets of lysine acetylation (54,56). Therefore, TgElp3 likely acetylates 
novel substrates located near or within the mitochondrion. 
 
E. TgElp3 performs an essential function at the mitochondrion 
The function of Elp3 in protozoans is unknown and widely debated in 
higher eukaryotes. However, disruption of this KAT in several species has been 
shown to cause significant defects, underscoring the importance of Elp3 in 
cellular physiology. Deletion of Elp3 in Arabidopsis impaired the mitotic cell cycle 
as well as leaf polarity (81,82,134). Migration and differentiation of mouse cortical 
neurons was significantly altered when Elp3 was decreased (70), and deletion in 
Drosophila caused larval lethality (83,84). Our results strongly support our 
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hypothesis that TgElp3 is essential for parasite viability. The genomic locus of 
TgElp3 could only be disrupted when an ectopic copy was present. The parasites 
apparently require TgElp3 but only a low level of protein is necessary for survival. 
mRNA and protein expression data provided on the Toxoplasma online database 
(toxodb.org) indicate that native TgElp3 is expressed at a low level, making 
conditional knockout or knockdown studies difficult. Using our ΔTgElp3:: 
ddHATgElp3 clone, we attempted to reduce TgElp3 protein levels by growing 
parasites in the absence of Shield-1. However, using the destabilization domain 
approach often results in residual protein present in the cell. We found that even 
in the absence of Shield-1, ectopic TgElp3 was present at a high enough level for 
the parasites to function normally. Alternative approaches will be needed to study 
the role of TgElp3 and why it is essential. In addition to showing TgElp3 is 
essential, our data indicates that its mitochondrial localization is important for its 
vital function. We were unable to obtain viable parasite clones when the region 
encoding the TMD was removed from the genomic locus encoding TgElp3. The 
TMD of TgElp3 is necessary for its mitochondrial localization and required for 
parasite survival.  
The mitochondrion has been a largely understudied organelle in 
Toxoplasma, and its functions in the parasite are poorly understood. 
Furthermore, several mitochondrial components and pathways appear to be 
lacking in Toxoplasma. For example, the Toxoplasma genome contains a few 
predicted orthologues of the mitochondrial import system such as Tim17, Tim22, 
Tim23, Tim44, Tom40 and heat shock protein 60 (135,136) but most of the 
import machinery has yet to be identified, and the mechanism of protein import is 
unknown. In general, the most well-known function of mitochondria is the 
involvement of the tricarboxylic acid cycle and electron transport chain in the 
production of ATP. Most components of the electron transport chain are encoded 
in the genome with the exception of some subunits of the ATP synthase complex 
but this pathway has yet to be characterized. While the Toxoplasma 
mitochondrion generates an electrochemical gradient, as indicated by the uptake 
of stains such as MitoTracker, the importance of mitochondrial respiration is not 
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known. Other important functions of the mitochondria that remain poorly 
understood include iron-sulfur cluster synthesis, heme biosythensis, and acetyl-
CoA production. One reason for the lack of information regarding these 
mitochondrial processes in Toxoplasma is because they also occur in the 
apicoplast, a more intensely studied organelle due to its unique and essential 
presence in apicomplexans.      
The function of TgElp3 at the mitochondrion is unknown and may require 
the radical SAM domain, KAT domain, or a combination of the two. We have 
shown that TgElp3 can function as a KAT, and homology of the radical SAM 
domain suggests it may also have catalytic activity. As previously mentioned, the 
orientation of TgElp3 in the outer mitochondrial membrane allows for interaction 
with cytoplasmic and mitochondrial associated proteins. This position is ideal for 
detecting cellular stress and relaying the signal between the mitochondrion and 
the rest of the cell.  TgElp3 may acetylate outer mitochondrial membrane 
proteins and/or proteins that are actively being translocated into the 
mitochondrion. For example, acetylation of the outer mitochondrial membrane 
pore-forming protein porin by TgElp3 may regulate the passage of proteins 
through the mitochondrial membrane. In addition to KAT activity, it is probable 
that TgElp3 performs other functions at the mitochondrial surface through its 
radical SAM domain. Radical SAM domains form iron-sulfur clusters that are 
used to catalyze reactions by binding and cleaving SAM, forming the 5’-
deoxyadenosyl radical. Iron-sulfur clusters are critical components of the electron 
transport chain, several metabolic processes, and mitochondrial iron 
homeostasis (137-139). Perhaps the iron-sulfur cluster of TgElp3 is critical for 
iron maintenance at the mitochondrion. Alternatively, the two domains may work 
together, requiring both to perform the function of TgElp3. Further studies are 
necessary to pinpoint the vital role TgElp3 plays in parasite physiology and the 
contribution of its catalytic domains.  
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F. TgElp3 as a potential drug target 
 We have shown TgElp3 to be a unique KAT with an outer mitochondrial 
membrane localization that is essential for parasite survival. TgElp3 has several 
characteristics that warrant further investigation as a potential drug target for 
treating Toxoplasma infection. Since it is essential, inhibiting TgElp3 could kill 
tachyzoite parasites during acute infection and potentially help prevent transfer of 
parasites from mother to fetus. Current KAT inhibitors work by binding and 
inhibiting the highly conserved KAT domain but because the KAT domain is 
present in several different proteins, these inhibitors are often non-selective and 
cause off-target effects. In addition, KATs are often highly conserved between 
species, and compounds can inhibit both the parasite and human host enzymes, 
causing toxicity. Fortunately, TgElp3, which could still be targeted with KAT 
inhibitors, could also be targeted more specifically thanks to the presence of a 
unique TMD not present in the human Elp3 homologue. By disrupting the 
targeting of TgElp3 to the mitochondrion, which we have shown to be lethal, it 
may be possible to specifically inhibit a critical enzyme in a parasite-specific 
manner. TgElp3 also has N- and C-terminal extensions that have no homology to 
human proteins. By targeting a different region of the protein, we may also be 
able to specifically inhibit TgElp3.  
  
	   74 
V. FUTURE STUDIES  
The work described in this thesis was the first characterization of an Elp3 
homologue in Toxoplasma. Our exciting findings have justified the continued 
study of TgElp3 and have led to a number of new questions to be answered. A 
key question that remains unanswered is, “What is the function of TgElp3 at the 
mitochondrion?” Our data suggest that its mitochondrial localization is vital for 
parasite survival but we are unclear what role(s) it plays at the outer 
mitochondrial membrane.  
 
A. Uncovering the role of the radical SAM and KAT domains 
Several approaches can be taken towards addressing the above question. 
One approach would be to determine the effect of each domain, radical SAM and 
KAT, on the parasites. We have shown that TgElp3 possesses KAT activity and 
that its radical SAM domain contains the conserved sequence necessary for 
catalytic activity. Therefore, we would like to test if one or both of the domains is 
necessary for TgElp3’s function by mutating key residues within the domains that 
would eliminate activity. Previous studies have shown that mutating two tyrosine 
residues in the KAT domain to alanines (Y715A and Y716A) greatly reduces 
activity (63,140). Also, radical SAM domain function can be disrupted by mutating 
any of the key cysteine residues in the CxxxCxxC conserved motif to alanine 
(C280A, C284A, or C287A) (62,140). Ideally, mutations would be made in the 
genomic locus of TgElp3, but alternatively, an ectopic copy of mutated cDNA 
could be introduced into the genome followed by deletion of the endogenous 
locus. Resulting parasites could be studied for defects in growth, and subsequent 
analysis could be performed to determine what aspect of parasite biology is 
affected by mutation of each or both of the domains. 
 
B. Using an inducible system to study TgElp3 function  
Another global approach to pinpointing the function of TgElp3 would be to 
create an inducible knockdown or knockout of TgElp3. Since we were unable to 
knockout the endogenous locus, inducible systems will need to be employed in 
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order to study the role of TgElp3. It is important to note that RNAi techniques 
have largely been unsuccessful in Toxoplasma. However, there are currently two 
independent techniques that could be attempted. One involves the use of the 
destabilization domain as described in section III-K. We suspect our attempt 
using this system was unsuccessful because low levels of TgElp3 are sufficient 
for function and our clones, when knocked-down, still contained sufficient levels 
of enzyme. This result was most likely due to the introduction of multiple ectopic 
copies that were expressed using the strong Toxoplasma tubulin promoter. A 
more tightly regulated system could be obtained by introducing a single ectopic 
copy into the genome expressed under the native TgElp3 promoter. Therefore, 
when the endogenous locus is removed, the ectopic copy would be expressed 
similarly to endogenous. In the absence of Shield-1, very little or no TgElp3 
should be present and a phenotype could be observed. The other inducible 
approach would be a modified version of the cre-lox system that was recently 
established in Toxoplasma (141). Cre recombinase, the enzyme responsible for 
recognizing loxP sites and excising the gene of interest, would be introduced into 
the Toxoplasma genome in two inactive fragments that requires rapamycin in 
order to dimerize and become functional (142). LoxP sites would then be 
introduced at the TgElp3 locus in parasites expressing the two Cre recombinase 
fragments. With the addition of rapamycin, the locus would be removed and the 
TgElp3 knockout phenotype could be studied. This technique was used by 
Andenmatten et al to create conditional knockouts of the following genes in 
Toxoplasma: gliding motor myosin A, the micronemal protein MIC2 and actin 
(141). All three proteins, previously determined to be essential, were able to be 
studied and were identified as part of a novel parasite invasion mechanism.   
 
C. Identification of TgElp3 substrates 
An additional tactic for uncovering the function of TgElp3 is to identify its 
substrates. As was mentioned in the discussion, TgElp3 is an outer mitochondrial 
membrane KAT with its domains facing the cytosol, allowing it access to a 
number of cytosolic and mitochondrial substrates. Our Toxoplasma acetylome 
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analysis identified the outer mitochondrial membrane porin to be highly 
acetylated. Based on proximity, porin would be an ideal protein to test as a 
potential substrate of TgElp3. However, testing potential substrates one-by-one 
is time consuming. Therefore, more global studies should be employed to identify 
proteins targeted by TgElp3. One such technique would be a parasite-wide 
acetylome analysis to compare acetylated residues in a wild-type strain versus a 
TgElp3 knockdown, with the expectation that substrates of TgElp3 would have 
lower levels of acetylation in the knockdown strain. Additional in vitro and in vivo 
experiments would be required to confirm that those found in the analysis were 
true substrates. An alternative strategy would be the application of click-
chemistry in a global search for substrates. In this approach, purified TgElp3 
would be added to total parasite lysate along with 4-pentynoyl-coenzyme A, an 
alkynyl chemical reporter. Therefore, substrates acetylated by TgElp3 will also 
contain the reporter, which can then be attached to biotin and isolated for 
identification by mass spectrometry. By identifying substrates of TgElp3 we will 
have a better understanding of the cellular pathways it regulates and how it 
functions.  
 
D. Establishing TgElp3 as a drug target 
Ultimately, we hope that future studies involve the identification of 
compounds to target TgElp3 for both therapeutic benefit and as useful reagents 
for the further study of this KAT. All of the studies described in this thesis used a 
type I, hypervirulent strain of Toxoplasma not normally found in human infections. 
Future studies should include the disruption of TgElp3 in a type II strain that can 
form bradyzoite cysts. If TgElp3 were found to be essential in this strain as well, it 
would further underscore its suitability as a target for therapeutic development. 
Another step in drug development would be a large-scale screen of compounds 
to identify those that inhibit TgElp3. By identifying or designing small molecule 
inhibitors, we could pharmacologically inhibit and study the function of TgElp in 
Toxoplasma and other apicomplexans. Currently, no TgElp3-specific inhibitor 
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exists. We would also be able to use those compounds in a mouse model of 
infection, bringing this research one step closer from the bench to the bedside.  
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VI. SUMMARY 
 Acetylation is a critical post-translational modification regulated by multiple 
KATs throughout the cell. Histone acetylation has been the best characterized to 
date, in part due to the nuclear localization of well-known KATs such as GCN5. 
However, with the increased availability and sensitivity of large-scale proteomics 
studies, global cellular acetylation has been characterized for several species, 
and the extent of protein acetylation is just now being understood. The challenge 
has now become to identify the enzymes responsible for protein acetylation and 
the role of this post-translational modification in regulating cellular pathways. 
Several advances have been made in identifying novel substrates of well-known 
KATs and characterizing previously unidentified KATs.  
This thesis describes the first Elp3 KAT homologue from an apicomplexan 
parasite, which exhibits unusual features suggestive of new functions across 
species. Most striking is the presence of a unique C-terminal TMD that targets 
TgElp3 to the mitochondrial surface with an orientation consistent with that of a 
tail-anchored membrane protein. Such an arrangement provides TgElp3 with 
great flexibility to acetylate a wide variety of substrates, both cytosolic as well as 
proteins associated with the mitochondrion. These unexpected findings prompted 
us to test if Elp3 localizes to the mitochondria in other species, and we found a 
processed form of mouse Elp3 localized to the mitochondria in neural cells. Since 
most Elp3 homologues, including mouse, do not contain the C-terminal TMD, the 
localization and perhaps function of Elp3 may be conserved but the targeting 
mechanism differs between Toxoplasma and other species.  
 We established that TgElp3 is essential for parasite survival and that this 
is dependent on its mitochondrial localization. The precise function of TgElp3 
currently remains unclear but a number of approaches outlined above can be 
used to identify its substrates and the role(s) of TgElp3 in parasite physiology. 
Identifying the substrates and functions of Elp3 in ancient eukaryotes, particularly 
apicomplexan parasites, which possess homologues that are likely mitochondrial 
tail-anchored proteins, will provide a much better understanding of the 
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importance of this protein throughout evolution and may open avenues for 
targeted therapeutic development.    
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